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Abstract
The use of natural products for treating protozoan infections can be traced back to
Rome in 1631, where cinchona tree bark was used to cure malaria. The discovery of
novel naturally derived compounds for the treatment of cutaneous leishmaniasis and
toxoplasmosis is vital for many vaccine deficient protozoan infections today. Here,
the assessment of natural products against Leishmania mexicana (L. mexicana) was
explored using a library of compounds screened against the mammalian stage of
L. mexicana in in vitro assays. Two hit compounds from the screen were then
used in metabolomic studies to determine mode of action. In addition, another
natural compound, Aureobasidin A and its derivatives, and peroxisome inhibitors
were screened against Toxoplasma gondii (T. gondii).
Peroxisomes are organelles involved in the metabolism of fatty acids and choles-
terol. Other than lipid metabolism, peroxisomes contain many enzymes involved
in several different metabolic processes. Catalase is involved in the neutralization
of hydrogen peroxide thereby, preventing toxic build up within cells. This enzyme
over time has become a key identifier of peroxisomes in many organisms. However,
this is controversial when it comes to T. gondii. The use of catalase as a marker for
peroxisomes in this parasite has been disputed, and in some cases led to the belief
that the T. gondii does not possess these organelles. In this thesis, we take a dif-
ferent approach in to establishing the existence of peroxisomes. Through evolution
T. gondii has maintained, within its genome, genes encoding peroxisomal proteins,
named peroxins (Pex). Here we investigated the presence of peroxisomes within
T. gondii using Pex proteins. Our experimental approach involved characterization
of putative TgPex5 and protein ligand TgSCP2. Using molecular biology, reverse
genetics and protein characterization, we show that through pull-down assays, lo-
calisation and complementation of TgPex5 in yeast expression systems, we are able
to provide evidence to prove the presence of peroxisomes within T. gondii.
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Chapter 1
Introduction
1.1 Protozoan diseases
Protozoan diseases are one of the World’s deadliest killers and present a severe threat
to global health. The World Health Organisation (WHO), estimate that these dis-
eases account for approximately 5 million deaths a year, predominately affecting the
World’s poorest nations. These unicellular eukaryotic organisms, include; malaria
(caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmod-
ium malaraie), Chaga’s disease (caused by Trypanosoma cruzi) /African sleeping
sickness (caused by Trypanosoma brucei rhodesiense, brucei gambiense), amoebia-
sis (caused by Enthamoeba histolytica), leishmaniasis (caused by Leishmania major,
dovnvini, mexicana etc), toxoplasmosis (caused by Toxoplasma gondii) to name a
few.
These protozoan diseases have no available vaccines; malaria caused by Plasmod-
ium and transmitted by mosquitos has many front-line drugs, but most of these are
under a constant threat of developing drug resistance [1, 2]. To date there are no
commercial available vaccines, and although there has been significant research into
the malaria RTS-S vaccine, the vaccine has shown limited success in only providing
50% protection [3]. Currently this shows that there is no long-term immunization
towards malaria. T. brucei, another well known protozoa, but transmitted by teste
1
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fly and unlike malaria is classed as a neglected tropical disease and brings about
African sleeping sickness but like other protozoan infections, lacks in drug thera-
peutics and has no known vaccine. There are few compounds used to treat African
sleeping sickness, including pentamidine, suramin, melarsoprol, eflornithine, and ni-
furtimox [4, 5], and therefore, there is also a need to investigate the discovery of
novel treatments. This lack of effective treatments for all of the above mentioned
parasites has led many of these endemic areas to focus on other areas of disease pre-
vention methods. For example; combined efforts of the use of bed nets and outdoor
residual spraying, preventing vectors from spreading disease. Here a combination of
insecticide usage (mainly DEET (N,N-diethylmetatoluamide)) together with the use
of front-line treatments are both used to combat disease and have lead to many suc-
cess stories as reported by the Center for Disease Control (CDC) and the WHO [6].
However, over many years the world has seen both increasing rates of insecticide and
drug resistance, and many researchers have looked into the development of synthetic
compounds [1, 2, 7–9]to tackle up coming resistance.
1.1.1 Protozoa: a global burden and need for new treatments
and novel drug targets.
The research focus on drug discovery leading to novel anti-parasitic drug therapies,
instead of parasitic vaccine development can be attributed mainly to cost. Vaccine
trials require large cohorts of patients, volunteers, and staff which are costly in
comparison to drug trials. However, more importantly, the complicated multistage
life-cycles of these parasitic organisms makes the development of effective treatments
very complex as shown in Figure 1.1. Many pathogenic protozoa have evolved
complex life cycles in order to survive in their host(s). These sometimes involve a
direct or monoxenous life cycle using a single host or an indirect or heteroxenous
life cycle involving more than one host, therefore having more than one infected
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reservoir to tackle when it comes to interventions of drug, vaccine or insecticide
development.
Figure 1.1: Drug-discovery programs targeting different stages of the protozoan life cy-
cle: (A) Monoxenous or direct life cycle is where only one host is involved where the
protozoa spends most of its mature adult life and where it reproduces. Whereas in
a (B) heteroxenous or indirect life cycle two or more hosts are involved and there-
fore include an intermediate stage, making the life cycle more complex. Microsoft
images and (https://www.dreamstime.com/stock-illustration-human-fetus-concept-illustration-as-
prenatal-growing-baby-umbilical-cord-white-background-as-obstetric-medicine-image68323107)
All parasites following this general pattern of growth and development stage
(maturation), reproduction (to include sexual and asexual) and transmission phases.
It is these three different stages that drug discovery programs have exploited in the
past, by developing stage specific compounds such as transmission blocking drugs,
and compounds that affect the metabolism, mobility and protein expression [10].
Often over the past decades efficacious treatments showed toxicity with significant
side effects as discussed in later. The emergence of drug resistance has meant that a
search into novel compounds and new target identification and validation programs
all over the world are even more vital. [11–13].
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In this global fight against protozoan disease, two things have come into favour;
one is increased funding; for example UK government in 2015 gave financial support
for research in Neglected Tropical Diseases (NTDs) such as leishmaniasis. This has
lead to collaborations between public and private institutions for example the 2012
London Declaration on NTD’s (https://www.gov.uk/government/publications/2010-
to-2015-government-policy-health-in-developing-countries/2010-to-2015-government-
policy-health-in-developing-countries). The other is, the sequencing of protozoan
genomes which has undoubtably helped in the discovery of many new molecular
drug targets by focusing on parasite genetics. Research into these key areas, in ad-
dition to understanding of the different stages of the protozoan life cycles, are hoped
to lead to the development or discovery of novel anti-parasitic compounds.
1.1.2 Leishmania and Toxoplasma
Why Leishmania and Toxoplasma ?
When it comes to leishmaniasis, the world has seen an increase in cases over
the past decade in many areas where there had been a reduction of disease [14].
The reason for this can be attributed to an increase in poverty, which results in
poorer healthcare and other social economic issues. Countries that have seen a rise
in leishmaniasis include war-stricken zones like: Pakistan, Iraq, Saudi Arabia and
Syria [15,16]. Pre-conflict statistics in Syria show that there were approximately 23
000 cases per year in 1992, rising to 41 000 cases a year in 2012 [17]. In Pakistan, the
displacement of people led to a 3.61% rise in the cases of leishmaniasis in war-affected
Waziristan [14]. Also Kenya despite not being a war zone, experienced an outbreak
in June 2017 as reported by WHO (WHO). This increase in leishmaniasis in regions
affected by conflict (Figure 1.2 ) demonstrates the need for novel treatments and
interventions in response to these outbreaks.
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Figure 1.2: Number of cutaneous leishmaniasis (CL) cases from 1989 to 2011 in the Middle East.
Taken from Salam et al 2014 [15]
Unlike leishmaniasis, toxoplasmosis is a significant threat to all unborn mam-
malian foetuses world-wide (WHO). Immunocompetent humans infected with Tox-
oplasma can live with the parasite symbiotically without showing any symptoms of
disease. However, immunocompromised individuals including those with AIDS or
cancer, when infected with the parasite do exhibit disease symptoms and require
treatment [18]. Likewise, uninfected pregnant mothers are at risk of losing their
unborn offspring, when infected by the parasite in their first trimester of pregnancy,
which usually results in the loss of (infant) life [19]. Toxoplasmosis is also known
to impact farms where livestock is a main source of income. This need to protect
the unborn foetus highlights the importance of discovering new drug targets, target
validation and also development and investigation into new therapies for animals
and humans against Toxoplasma.
Research into the genetics of Toxoplasma by scanning through it’s genome has
previously helped identify key genes from T. gondii that have potential as putative
1.2. Toxoplasma gondii 6
drug targets [20, 21]. In addition, other approaches for drug discovery include the
use of screens, employing various in vitro drug assays with novel compounds, with
the aim of identifying new treatments for toxoplasmosis [22, 23]. Additionally, the
discovery of new drug targets within this parasite, such as the existence of an or-
ganelle within T. gondii, and assessing whether it has drug potential, could also lead
to new treatments for toxoplasmosis [24].
1.2 Toxoplasma gondii
T. gondii is a protozoan parasite of the apicomplexcan family, that was discovered
over 100 years ago in mammals by Nicolle and Manceaux [25].
1.2.1 Toxoplasma gondii
As an obligate intracellular pathogen Toxoplasma lives in host cells and has unique
aspects to its cell biology and exists in various different cellular stages (Figure 1.3 )
as tachyzoites, bradyzoites, and sporozoites. [19,25]. Tachyzoites are crescent shape
and range in size from 2-6 mm, and typically have three membranes consiting of
a plasmalemma and two other membranes that form an inner membrane complex.
They also know to posses all the usual eukaryotic organelles such as endoplasmic
reticulum, golgi bodies and a nucleus, the latter located towards the centre of the
cell [26]. This form of the parasite multiplies rapidly in any cell of an intermediate
host and within the intestinal cells of the definitive host. It enters these cells by
actively penetrating through the host cell plasma membrane or by phagocytosis [26].
Once in the cell, tachyzoites asexually multiply by repeated endodyogeny in which
two progeny form within the parent parasite. This ruptures the host cell as soon
as it can no longer support the growth of the parasite and releases tachyzoites that
subsequently infect other cells within the tissue [26]. Some of the tachyzoites in
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Figure 1.3: Toxoplasma gondii parasite sexual This cycle shows the various stages and forms of
the parasite to including tachyzoites, bradyzoites and oocysts [27].
the infected host cells then develop into bradyzoites, which are contained within a
tissue cyst. These cysts can be found in cells of the liver, lungs, brain, eyes and
both skeletal and cardiac muscles and vary in size ranging from 5 -100 mM, enclosing
hundreds of crescent-shaped bradyzoites [26]. Bradyzoites are similar to tachyzoites
but are thinner in appearance, have the nucleus located towards the posterior end
and are less susceptible to destruction by proteolytic enzymes when compared to
tachyzoites. The other notable difference is in the pre-patent period (which is the
time it takes to shed parasites within a cat host) such that, when a cat has had a
meal with tachyzoites the period is longer, whereas if it has consumed bradyzoites
the period is shorter. The ingestion of these two stages and sporozoites results in
the infection of feline intestinal tissue [26,27].
Once infected by either the tachyzoites or cyst, proteolyitic enzymes within the
cat gut break down the cyst wall allowing the penetration of bradyzoites into the
intestinal cells. These parasites first multiply asexually, followed by the sexual cycle
1.2. Toxoplasma gondii 8
which occurs after approximately 2 days later. Here microgametes penetrate and
fertilize mature macrogametes to form zygotes. After fertilization, an oocyst wall
forms around the parasite giving it a spherical shape and size of approximately 10
mM. The cat then starts to shed unsporulated oocysts after approximately 10-18
days after the infection where the unsporulated oocyst, sporulate after 1-5 days in
the external environment [26].
1.2.2 Toxoplasma gondii life cycle in indifinative and defini-
tive host
The zoonotic nature of Toxoplasma has both a sexual and asexual stage within
their life cycle. The tachyzoite form found in infected muscle tissues of mammals
for example, pigs, cattle, humans and mice, are known as indifinative hosts. During
the T. gondii life cycle, a Toxoplasma infected mouse known to be attracted to
the urine of domestic cats, as a result of some alternation in their neurological
pathways, renders the mouse fearless towards cats, making them easy prey. The
cat is the definitive host and once infected by tachyzoites or bradyzoites travel to
the intestinal tissue where they mature sexually from tachyzoites or bradyzoites
into unsporolating oocysts. Unsporulating oocysts are then shed approximately two
weeks after infection into soil or litter tray where after excretion depending upon
aeration and temperature, the oocysts sporulate and spread into the environment.
These oocysts can then contaminate other food and water sources, and thereby
transmitted to other mammals, including humans. Contaminated food sources are
often in the form of uncooked meat and raw vegetables that come into direct contact
with infected cat faeces from soil but can also be transmitted directly between
humans. Blood transfusions are also a source of T. gondii transmission in humans
showing that there are four possible routes of infection resulting in toxoplasmosis
Figure 1.4 [28].
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Figure 1.4: Life cycle of Toxoplasma gondii . The cycle starts from an infected intermediate
host such as rodents, and other mammals including pigs, sheep and cattle. T. gondii at this
stage in its life cycle is in its tachyzoite or bradyzoite stages and passes on to the definitive host
through ingestion of an infected mouse. In the cat, the parasite completes its life cycle by shedding
unsporelated faecal oocysts. Oocysts then develop into sporulated oocysts which, if they come into
direct contact with human food sources are consumed, lead to T. gondii infection. [28]
1.2.3 Toxoplasmosis
Toxoplasmosis is caused by T. gondii was first identified as a disease in the tissues
of a congenitally infected infant in 1939 and today affects a third of the world’s pop-
ulation [19]. T. gondii is known to thrive in immunocompromised individuals and
affects pregnant women, leading to either spontaneous abortion of the foetus or chil-
dren born with toxoplasmosis as shown in Figure 1.5. If a woman becomes infected
with T. gondii during pregnancy, this usually results in a miscarriage, a stillborn
child, or a child born with congenital toxoplasmosis usually evident by an abnor-
mally enlarged head [19]. Currently, there are few available drug treatments (Table
1.1) for pregnant women who become infected with T. gondii after conception. As
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for immunocompromised individuals, the AIDS epidemic over the last three decades
has resulted in an increase in T. gondii related infections (Figure 1.6), Reactivation
of the parasite in HIV infected individuials leads to symptoms of fever, seizures and
poor coordination, while those that acquire HIV first and subsequent T. gondii ex-
posure develop a severe primary infection, leading to Toxoplasma encephalitis [18].
This opportunistic pathogen can cause similar symptoms in other immunocompro-
mised individuals such as cancer patients (NHS). Today, toxoplasmosis as reported
by the CDC infects 22.5% of the population in the USA, while in some countries
like Brazil infection rates are reported to be as high as 95% (CDC). In the United
Kingdom, 350 000 people in the population were estimated to be infected with this
parasite (NHS, 2015). All of these infections together indicate an urgent need for
the discovery of new therapies.
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Figure 1.5: Children with various forms of toxoplasmosis; Fetus born with TORCH Syndrome
or commonly known as Chronic Congenital Infection Syndrome has a range of complications to
include damaged organs and Central Nervous System abnormalities and the fetus’ chances of
survival at this stage are quite reduced (A)(From Dubey JP, and Beattie CP. Toxoplasmosis of
animals and Man. CRC Press, Baca Raton, Florida, 52, 1988). While a child with the ocular form
of the disease and will suffer from blurred vision and photophobia and in some cases blindness (B)
(http://www.infonet-biovision.org).Hepatosplenomegaly as shown in (C) is another type of fetal
toxoplasmosis.
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Figure 1.6: World map showing toxoplasmosis infections in association with increase in AIDS.
The map clearly shows that the low income countries are the most affected and as a result of poor
education, sanitary conditions lead to increases in toxoplasmosis mainly as a secondary infection
[18]
1.2.4 Current treatments for toxoplasmosis
As shown in Table 1.1 current medicines for toxoplasmosis include a combination
of therapies for different patients and consist mainly of pyrimethamine and sulfa-
diazine and leucovorin used in the prevention of haematologic toxicity. A review
of 115 patients with Toxoplasma encephalitis found side effects of this combination
therapy, leading to 44% of patients requiring a change of treatment [29]. The use of
pyrimethanmine and sulfadiazine is also associated with severe liver necrosis, toxic
epidermal necrolysis and agranulocytosis [30]. This highlights the importance of
researching into discovery of new therapies that would be less toxic to patients. In
addition to the high levels of toxicity associated with current modes of therapy, the
problem of drug resistance is suspected to contribute to approximately 10% of treat-
ment failures [13]. Clinical isolates with high levels of sulfonamide resistance have
been found due to mutation in the dihydropterate synthase gene which includes
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sulfadiazine, [13]. In addition to the toxicity and resistance presented by current
drugs used to treat toxoplasmosis, the long treatment durations form several weeks
to years are also problematic. The prolonged treatment regime is in part due to lack
of drug efficacy against T. gondii tissue cysts during a treatment course. This again
highlights the need and importance of new discoveries for treatments to be focused
on compounds that would eliminate tissue cysts from the host cell, non-toxic and
have a potential to be used in chronic infection as well as being safe to use during
pregnancy [30].
name of
treatment
Demographic Molecular Target
Spiramycin (1st
trimester) and
pyrimethamine
sulfadiazine and
leucovorin (2nd and
3rd trimester)
Pregnant women,
newborns and
infants
Dihydrofolate
reductase
essential for
DNA and RNA
synthesis
Pyrimethamine and
sulfadiazine plus
folinic acid
People with
ocular
toxoplasmosis
Dihydrofolate
reductase
Anti-retrovirals
followed by
pyrimethamine and
sulfadiazine plus
folinic acid
Immunocompromised
individuals; AIDS
usually in the
form of
toxoplasmic
enchephalitis
Dihydrofolate
reductase
Pyrimethamine and
sulfadiazine plus
folinic acid
Healthy non
pregnant
individuals
Dihydrofolate
reductase
Table 1.1: Treatments for toxoplasmosis as reported by the CDC and WHO. [13,30]
1.2.5 Drug discovery
As with all protozan research, drug discovery for toxoplasmosis poses many chal-
lenges primarily due to cost and the poorly understood biology, especially in the
Felidae stages of the parasite but also in bradyzoites and tachyzoite forms. Some of
the difficulties in therapy research can be attributed to two main causes. Firstly the
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tough glycan-rich cyst wall of the bradyzoite is difficult to penetrate and has been
a major hindrance in exploring this stage of the parasite. Secondly, the lack of an
animal model that resembles T.gondii infection in humans. Despite these difficulties
the development of rapid and reproducable in vitro drug assays makes the search
for T.gondii therapeutics more achievable [30] [22]. T. gondii tachyzoite inhibition
assays are often used and the RH strain of Toxoplasma is well adapted to in vitro
culture. T. gondii bradyzoite inhibition assays, however, are not well established
but are a crucial tool in research into encysted parasites. In addition, databases such
as ToxoDB provide valuable information on genes that can be exploited to target
specific proteins within organelles or the organelles themselves. T. gondii genome
sequences are now available for ME49 (a Type II strain) and GT-1 (a Type I strain),
and sequence alignments of these strains are available as genetic maps and single
nucleotide polymorphisms (SNPs) alongside the commonly used Type I RH labora-
tory strain has allowed a better understanding of this obligate pathogen [31]. The
ER and mitochondria of Toxoplasma offer excellent drug targets and some inhibitors
have been identified that target these organelles and a similar approach would be to
investigate an organelle [30]. The peroxisome is another organelle within T. gondii
that offers significant potential as a target for novel.
1.2.6 Peroxisomes
Peroxisomes were first identified by Christian de Duve in the 1960s [32]. He first iden-
tified them in rat liver and later in protozoa, namely Ancathamoeba and Tetrahymena
pyriformis. These early biochemical studies described peroxisomes as membrane-
bound micro-bodies containing catalase and hydrogen-peroxide [32]. This well stud-
ied, functionally-diverse organelle, located in the cytosol of all eukaryotic cells has
been linked to many catabolic functions (Figure 1.7). These include long chain fatty
acids, branch fatty acids, D-amino acids, plasmogen synthesis, amino degradation
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and purine metabolism [33,34]. Their functionality varies between organisms, for ex-
ample, in animals, peroxisomes are involved in trafficking cholesterol, while in plants,
as well as being involved in conversion of fatty acids to carbohydrates, they also play
an important role in photorespiration (a process in plant photosynthesis) [33].
Figure 1.7: Biochemical processes in mammals adapted from Schrader et al [35]. The enzyme
catalase breaks down hydrogen peroxide into water and oxygen
Peroxisome functionality is brought about by a group of proteins called peroxins
(Pex). To date there are 32 known peroxins inculding; Pex1, Pex2, Pex3, PexMP3,
Pex5, Pex6, Pex7, Pex10, Pex11A, Pex11B, Pex12, Pex13, Pex14, Pex16, Pex19,
1.2. Toxoplasma gondii 16
Pex26, Pex28, Pex30 and Pex31. [36]. In most organisms peroxins are involved
in trafficking post-translational proteins in the form of proteins bound to their co-
factors and/or as protein complexes [37]. Proteins transported to the peroxisome via
the peroxisomal matrix are recognised by two well known specific cytosolic receptors,
Pex5 and Pex7. These receptors have been identified as the key players in cholesterol
trafficking and lipid sorting. Transportation of lipids from the host cell cytosol to
the peroxisome is shown in Figure 1.8. To do this, peroxisomes rely on a group
of lipid carrying proteins also referred to as peroxisomal matrix proteins. There
are two types of these proteins, uniquely identified by a Peroxisomal Targeting
Signal (PTS). The first of these is PTS1 and is characterised by having these three
amino acid residues (Serine-Lysine-Leucine) at the C-terminus of the matrix protein.
The second, PTS2 has a sequence of R/K-L/V/I-X5-H/Q-L/A at the N-terminus.
Research in yeast (S.cerevisiae) shows that Pex7 binds to thiolase via PTS2. PST1
proteins that on have been identified include Sterol Carrier Protein-2 (SCP2) [38]
and catalase [24, 39]. SCP2, as its name suggests, moves sterol across membranes
and also intracellularly. It is well established that in order to transport sterol and
other cytosolic lipids, the PTS1 on SCP2 binds the C-terminus of Pex5 as a receptor
during lipid transportation, while the N-terminus of Pex5 binds to Pex7 [40–43].
The Pex5 cycle in yeast (Saccharomyces cerevisiae) commences in the cytosol and
involves the C-terminal end of Pex5 binding to the PTS1 of SCP2+(lipid) [41]. This
Pex5-SCP2+(lipid) complex then interacts with other peroxins, such as Pex13 and
Pex14 found in the peroxisomal membrane, allowing the SCP2+(lipid) to be released
into the peroxisome. Pex5 then undergoes ubiquitination by either Pex2, Pex10
or Pex12 which allows Pex5 to be recycled into the cytoplasm by Pex1 and Pex6
[44]. The Pex5 cycle in yeast involves some hydrophobic protein complexes that are
instead recognised by receptor Pex19 which binds to other peroxisomal membrane
peroxins such as Pex3 [42, 45, 46]. Using Figure 1.8 to illustrate, the hypothetical
TgPex5 (T.gondiiPex5) TgPex7 (T.gondiiPex7) cycle within T.gondii peroxisome
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would involve the C-terminus of TgPex5 binding to the PTS1 of TgSCP2+(sterol)
to form a complex of TgPex5-TgSCP2+ sterol which in turn would bind to the
TgPex7 receptor. This complex when docked on the peroxisomal membrane, would
allow the release of the sterol into the peroxisome matrix, while the TgPex5 receptor
is recycled for further lipid transportation.
The ability of peroxins to transport both hydrophilic and hydrophobic proteins in
most eukaryotes has been seen as essential. Mutations in the Pex genes (specifically
in Pex5) in humans results in Zellweger-Syndrome, Neonatal Adrenoleucodystro-
phy or Infantile Refsum’s disease, often leading to premature death [37]. These
finding highlight the essential functionality of peroxins during peroxisomal biogen-
esis, and also their importance in the transportation and metabolism of lipids and
other compounds such as hydrogen peroxide [35]. Despite the crucial role of perox-
isomes in humans and other eukaryotes (especially eukaryotes living in oxygen poor
environments), other protozoa have been reported to lack peroxisomes, including
intestinal parasites such as Giardia intestinalis and Enthamoeba histolytica. Intra-
cellular protozoan parasites such as the Microsporidia Encephalitozoon cuniculi and
the Apicomplexans Plasmodium falciparum, and Crptosporidium parvum have also
been reported to lack peroxisomes [47,48]. In contrast, flagellate kineoplastids Try-
panosoma and Leishmania, do have peroxisomes (glycosomes) and possess numerous
glycolitic enzymes but lack catalase. [49]. In helminths, however, the genes found in
peroxisomes seem to have been lost through evolution [34]. However, there is con-
flicting evidence for the existence of these organelles within toxoplasma and proof
for peroxisomes is sparse, however unlike the helmiths, T. gondii does posses many
peroxisomal genes (www.toxoDB.com). Here, we exploit information drived from
the Toxoplasma genome to analyse and experiment on the key peroxin Pex5 and
its associated protein SCP2. An interaction between this PTS protein and its re-
spective protein partner has been demonstrated previously in studies of peroxisomes
within Toxoplasma [50].
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1.2.7 Toxoplasma gondii peroxisomes?
Obligate intracellular organisms such as T.gondii rely on the host for most of their
nutritional requirements during infection, as they lack their own biological machinery
to synthsise cholesterol. This inability of T.gondii to synthesize its own cholesterol
makes it reliant on its mammalian host to provide these essential compounds. The
uptake of lipids, as in all organisms, is important for post-translational modification
of proteins as well as the building of membranes, making T.gondii heavily reliant
on the exogenous uptake of lipids. Host lipoprotein-derived cholesterol is crucial for
T. gondii replication. Nishikawa et al [21]showed that the absence and abundance
of low-density lipoproteins (LDL) resulted in encystation and over-replication re-
spectively [21]. These findings indicated that T.gondii evolved to allow trafficking
of cholesterol in terms of storage, acquisition and transportation. There apppear to
be various forms of cholesterol compartmentalization in T. gondii including unique
mechanisms, which allow uptake and storage of LDL [24]. Databases searches using
toxoDB have identified T. gondii genes encoding peroxins as well as their associ-
ated ligand binding proteins that carry PTS1 and PTS2 motifs (www.toxodb.org).
Previous studies, used catalase in the protozoa Ancanthaomoeba and Tetrahymena
pyriformis as as evidence for establishing the presence of these peroxisomes [32].
More recently, GFP fused to catalase was used to localise peroxisomes in T. gondii.
The result of these experiments in tachyzoite and bradyzoite stages of T. gondii,
showed that this fusion protein was mainly cytosolic and it was concluded that
T.gondii harbored no peroxisomes [51]. However, Kaasch and Joiner [52]also using
catalase as a marker suggested that there are peroxisomes in T. gondii using ex-
periments that showed the breakdown of H2O2 by catalase as an indicator of the
presence of peroxisomes. They defend this argument by suggesting that cytosolic
catalase would be insufficient to neutralise exogenous H2O2, whereas membrane-
bound micro-bodies with a pool of catalase would be needed to scavenge the H2 O2
production [52]. More recently, evidence of the presence peroxisomes in T. gondii
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has been supported by Lige et al. Their approach has been to use tagged GFP-
TgSCP2 in localisation studies [50].
In this project we adopted a similar approach to Lige et al, using a classical
protein-centred approach. We functionally and structurally analysed two key targets
TgPex5 and TgSCP2 with the goal of proving that these proteins function like
related Pex proteins from other organisms with peroxisomes in order to provide
support for the existence of this organelle in Toxoplasma.
1.2.8 Toxoplasma gondii Aims and Objectives
1. To purify the Pex proteins TgPex5 and TgSCP2, specifically the C-terminal
end of TgPex5 (TgPex5C-TERMINAL ) and the PTS1 domain of TgSCP2 (TgSCP2PTS1).
2. To assess localisation through protein-protein interactions, usingTgPTS1 bind-
ing to TgPex5 in wild-type T. gondii .
3. To evaluate TgPex5 in complementation studies investigating its functionality
in yeast and human Pex5 mutants.
4. Investigate the potential use of natural compounds and peroxin inhibitors
against Toxoplasma both in the tachyzoite and bradyzoite stages, by opti-
mising an in vitro assay and screening compounds against encysted T. gondii
and non-encysted forms of T. gondii.
1.3 Leishmania
Leishmania like Toxoplasma is a protozoan zoonotic parasite, and has vertebrates
as its primary host. [53].
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1.3.1 Leishmania life cycle
All Leishmania species have two structural variants, the promastigote and amastig-
ote as shown in Figure 1.9 . The mammalian life cycle of Leishmania begins with
a bite from the parasite’s vector the female phlebotimine sandfly which transfers
the promastigote form of Leishmania from the proboscis into the skin of a human
(anthroponotically), or through zoonosis. Here, while the sandfly vector is feeding,
metacyclic promastigotes are phagocytosed by either macrophages or neutrophils
and transformed into flagellated amastigotes [54]. Unlike other pathogens, the en-
dosomal lysosomal enzymes within the macrophage have no effect on Leishmania
allowing this parasite to grow and dividie through binary fission [28]. Ultimately,
this causes the macrophage to burst, thereby releasing more Leishmania amastig-
otes into circulation infecting more macrophages and allowing the cycle to repeat
until a sandfly takes its next blood meal. In the gut of the sandfly, the amastigotes
transform into promastigotes, these form by simple division changing from procyclic
to metacyclic promastigotes. These metacyclic promastigotes then migrate to the
pharyngeal valve, ready for the next infection [28].
Leishmania promastigotes have are elongated with a flagellum, which is mainly
used for migration from the sandfly gut to its probiscus, such that when cultured
in vitro, insect like gut conditions such as a temperature of 26ºC and a pH of 7 are
required. In contrast, the amastigote which is usually found in mononuclear phago-
cytes such as macrophages and the circulatory system of humans is oval or circular
in shape with no visible flagellum and characteristically favours a temperature of
37ºC and a pH of 5.5 in vitro.
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Figure 1.9: Life cycle of Leishmania in the human and dog stages starts with a bite from the
sandfly , transferring the promastigote stage of Leishmania from the probiscus to the human or
dog, where macrophages scavenge and engulf these promastigotes. While these promastigotes are
in the macrophages they transform into amastigotes and replicates these are taken up by sandfly in
it’s next blood meal. In the sandfly stage the ingested amastigotes are transformed in the midgut
of the vector back into promastigotes ready for another round of transmission. [28]
1.3.2 Leishmaniasis
Leishmania is comprised of many species (Table 1.2) including the L. donovani com-
plex with two species, L. donovani and L. infantum, and the L. mexicana complex
with three main species namely L. mexicana, L. amazonensis, and L. venezuelensis
which also includes L. tropica, L. major and L. aethiopica. Subgenus Viannia has
4 primary species; L. (V.) braziliensis, L. (V.) guyanensis, L. (V.) panamensis and
L. (V.) peruviana. Despite the large number of species, they are all morphologically
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very similar and can only be distingusied by molecular techniques. Leishmaniasis is
the disease that is caused by both old and new Leishmania species [55].
Old World Leishmania New World Leishmania
L. tropica L. mexicana (L. mexicana, L.
amazonensis, and L.
venezuelensis)
L. major L. [Viannia] braziliensis, L.
[Viannia] guyanensis, L.
[Viannia] panamensis, and
L. [Viannia] peruviana
L. aethiopica -
L. infantum -
L. donovani L. infantum or L. chagasi
Table 1.2: Old and New World species of Leishmania [55]
There are to date 30 known species that infect mammals, of which 21 are known
to infect humans and bring about three of clinical forms of disease: cutaneous,
mucocutaneous and visceral leishmaniasis (Figure 1.11 and Figure 1.5).
1.3.2.1 Cutaneous leishmaniasis
Cutaneous Leishmaniasis (CL) is the most common form of the disease and arises
from infection of epidermal tissue after promastigote host inoculation. Symptomati-
cally it is distinguished by the appearance of skin lesions or skin sores, which develop
within weeks of being bitten by the sandfly. These sores are known to change in size
as well as appearance, after starting out as bumps they develop into nodules, which
may be painless [28]. The lumps are predominately found under arms and on the
hand as shown in Figure 1.10 (C). The ulcerated form usually develops on exposed
parts of the body such as face, arms and legs and can cover these areas, bringing
about serious disability to the infected individual (CDC and WHO). CL is caused
by the, Old World species L. major, L. tropica and L. aethiopica and New World
species L. mexicana and is most common in Afghanistan, Brazil, Iran, Peru, Saudi
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Arabia and Syria (Figure 1.11).
1.3.2.2 Mucocutaneous leishmaniasis
Mucocutaneous leishmaniasis (MCL) also known as mucosal leishmaniasis and like
cutaneous forms of the disease is physically debilitating, causing permanent damage
of mucosal areas around the body. This can sometimes lead to partial or complete
destruction of mucosal membranes such as those found in the nose, mouth and
throat. The development of ML is a direct result of being infected by L. braziliensis,
which can spread from the infected ulcer to various mucosal membranes around the
body. The destruction of tissues in the surrounding mucosa (Figure 1.10 (A)) can
lead to complete or partial destruction of mucous membranes of the nose and mouth.
This disfigurement and resulting disability, exposes the sufferer to stigmatism and
in some cases they are considered outcasts in countries like Bolivia, Brazil and
Peru [15].
1.3.2.3 Visceral Leishmaniasis
Visceral Leishmaniasis (VL) also known as kala-azar (black fever) is the most severe
form of leishmaniasis, like MCL and CL it typically develops after a few months,
after being infected with VL specific Leishmania: L. donovani or L. infantum. In
VL the parasite attacks internal organs such as the spleen, liver (Figure 1.10(B))
and bone marrow, leading to gastrointestinal bleeding, bouts of fever, severe anaemia
and weight loss. Consequently, it is life threatening if not treated early, and fatality
rates have been reported to be is as high as 100% within 2 years in countries such
as Bangladesh, Brazil, India, Nepal and Sudan. In addition to these countries,
increases in cases of VL also appear as a secondary infection in patients infected
with HIV [56].
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Figure 1.10: There are three clinical forms of leishmaniasis are caused by different species of
Leishmania, and include clinical forms such as ; Mucocutaneous leishmaniasis mainly attacking
mucosal membranes of the body (A), Visceral leishmaniasis infection which results in an enlarged
spleen, liver and sever weight loss (B) and Cutaneous leishmaniasis found on the face arms and
legs (C) [6].
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Figure 1.11: Global map of Cutaneous (CL) and Visceral Leishmaniasis (VL). As can
be seen in both maps the number of VL cases was reported to be high in South Amer-
ica and the Middle East and parts of Eastern Africa. CL although the most common
form of leishmaniasis seems to have reported lower cases in 2015 according to these WHO
maps.https://www.dndi.org/diseases-projects/leishmaniasis/disease-background-vl/ accessed Nov
2018 and https://www.dndi.org/diseases-projects/leishmaniasis/disease-background-cl/ accessed
Nov 2018
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1.3.3 Current treatments for Leishmaniasis
Leishmaniasis is treatable when drugs are administered early during an infection [57].
Treatments for leishmaniasis are divided into three categories, namely; pentavalent
antimonials including meglumine antimonate and sodium stibogluconate, Ampho-
tericin B, an anti-fungal, and miltefosine. Pentavalent antimonials are the common
front-line treatment and the drug of choice, although there have been reports of drug
resistance against both antimonials. The development of resistance to pentavalent
antimonials has encouraged their replacement by the alternate anti-leishmanials Am-
photericin B and miltefosine, both of which are known to have good potentcy, but
also have major side-effects [57].
1.3.4 Current front-line anti-leishmanials
There are three main compounds used as frontline anti-leishmanials
1.3.4.1 Pentavalent Antimonials
Pentavalent antimonials shown in Figure 1.12 (a) and (b) were the first chemothera-
pies to be used against leishmaniasis in 1930 and include meglumine antimonate and
sodium stibogluconate. The mode of action of these antimonials is still unknown,
although it has been suggested that they target several pathways in the amastigote
stages including glycolysis, fatty acid beta-oxidation and inhibition of ADP phos-
phorylation [57]. These trivalent antimonials are the preferred drug of choice and
are administered at about 20 mg/kg/day for 20 days and have a successful cure
rate despite showing dangerous side-effects. A reduced safety profile after treat-
ment has been reported with patients experiencing severe headaches, pancreatitis
and cardiotoxicity, in 60% of leishmania sufferers in India known to be infected with
antimonial resistant forms of leishmaniasis [57]. In addition, drug-resistance against
these set of compounds has risen over the past 40 years, with the first drug resistant
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isolates being reported as early as 1980 where patients in Guatemala and India saw
the cure rate drop from 99%, to 86%, to 81% over a 4 year period [58].
(a) Sodium stibogluconate
(b) Meglumine antimonate
Figure 1.12: Molecular structures of pentavalent antimonials, sodium stibogluconate (a) and
meglumine antimonate (b) used in the treatment of leishmaniasis [57]
1.3.4.2 Amphotericin B
Amphotericin B (Figure 1.13) is a natural anti-fungal drug that was isolated from
Streptomyces nodosus in the 1950’s and used as an intravenous treatment for many
fungal infections including candidiasis, coccidioidomycosis, cryptococcosis to name
a few [59]. It is also used as a frontline treatment for leishmaniasis at 1 mg/kg/day
for 20 days and has cure rates of up to 99%. The mode of action involves the
development of pores within cellular membranes of the parasite, thereby causing an
imbalance of ions causing inevitable osmotic lysis [57]. There has been little evidence
of resistance developing against Amphotericin B, but the cost to the developing world
in 2010 was between $162-$229 per course of treatment [59], which is a significant
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cost and makes the drug unaffordable many parts of the world where leishmaniasis
is rife.
Figure 1.13: Molecular structure of amphotericin B [54]
1.3.4.3 Miltefosine
Miltefosine (Figure 1.14) sold under the trade name Impavido was first developed
and manufactured as an anti-cancer drug in the 1980’s [57]. It was subsequently
approved as an anti-leishmanial for use in India in 2002 and is currently still un-
dergoing clinical trials in other countries. Miltefosine is known to act on both the
dimorphic (both promastigote and amastigote) forms of VL and CL and is reported
to have a mode of action that involves inhibition of cytochrome c oxidase and may
also affect lipid metabolism [57]. A 28 day treatment regime exists for miltefosine
and ranges from 100 mg/kg/day for VL and 2.5 mg/kg/day in CL with cure rates
at up to 94% in VL. Not many cases of resistance have been reported to date but
side effects are reported 60% of the time in users and include nausea, vomiting,
diarrheoa, headaches and dizziness [57].
Figure 1.14: Molecular structure of miltefosine [57]
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Growing resistance to anti-leishmanial drugs, prolonged treatment regimes, high
toxicity and severe side effects has led to these treatments being reviewed. In addi-
tion, the current status of antilishemaninal drug discovery shows that the pipeline is
empty, remeaning that a small inventory of anti-leishmanial drugs are used to treat
all CL, MCL and VL cases. The increase in drug-resistant Leishmania as well as the
rise of leishmaniasis cases, highlights the need for a new, affordable, larger library of
compounds to treat Leishmania. The treatment of leishmaniasis over past decades
involving front-line drugs is costly (Amphotericin B), and causes severe side-effects
(Miltefosine) and in some cases, the emergence of drug resistance (pentavalent an-
timonials). As a consequence many research groups and endogenous people in both
endemic and non-endemic areas have explored, investigated and tested the use of
natural products, mainly plant derived in an effort to treat Leishmania (Tables 1.3
and 1.4) [60–63].
1.3.5 Natural products as anti-leishmanials
The use of natural products for treatment of protozoan disease dates back to 1631,
where the bark of the cinchona tree was used as a treatment for malaria in Rome.
This tree originated in Peru and was brought over to Europe by Jesuit priests and
used to successfully treat King Charles II. Following this success, cinchona bark (also
known as Peruvian bark) active componet in quinine, became popular in Europe and
was deployed as the primary anti-malarial until the 1940’s [64] where quinine was
replaced by other antimalarials due to drug resistance. The rescue of quinine resis-
tance in many endemic areas was by another natural compound called artmether.
Today the search for new chemotherapies from natural products extends to many
other protozoan diseases including the treatment of leishmaniasis [65].
1.3. Leishmania 31
1.3.5.1 Natural oil and wax extracts as anti-leishmanials
name mode of action Species of
Leishmania
Reference
Ferula galbaniflua
oil
Not Known Effective against
L. amazonensis
promastigotes
[63]
Tetradenia riparia
oil
Not Known Inhibits L.
amazonensis
promastigotes
and L.
amazonensis
infected
macrophages
[61]
Propolis tree resin,
bioflavonids and
waxes collected
from Apis mellifera
bees
Not Known Inhibits L.
amazonensis
promastigotes
and amastigotes
[62]
Table 1.3: Oil extracts from plants and trees used against Leishmania.
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1.3.5.2 Plant extracts; fruit, leaves and barks as anti-leishmanials
name mode of action Species of
Leishmania
Reference
Coccina grandis
leaf extract
Increases levels of
IL-12 and TNF-a.
Leishmania infection
usually blocks IL-12,
use of the drug
restores normal
immune function.
L. donovani
infected
macrophages
[66]
Euphorbia
prostrata leaf
extract
Cause necrosis of
parasite.
Inhibits growth
of both L.
donovani
promastigotes
and amastigotes
[67]
Physalis pubescens
fruit extract
Changes the
morphology of the
parasite.
Inhibits L.
amazonensis
promastigotes
[60]
Solanum
lycocarpum fruit
extract
Not Known. Inhibits L.
amazonensis
promastigotes
[68]
Ginger extract Not Known Inhibits L.
amazonensis
promastigotes
[69]
Lacistema
pubescens plant
extract
Not Known Inhibits L.
amazonensis
promastigotes
and L.
amazonensis
infected
macrophages
[70]
Table 1.4: Plant extracts from leaves, and barks used against Leishmania
As can be seen from the table above, there are many natural products which have
been tested against Leishmania parasites. Success in the use of natural products as
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anti-leishmanial agents in vitro is evident although the results mainly show success
in blocking th promastigote stages and non-infected macrophages. In tackling the
fight against leishmaniasis, all stages and disease causing species need to be targeted.
Exploiting large libraries of natural compounds is one of the ways we could combat
and develop new global treatments. Here the use of well established Leishmania
in vitro assays [54, 71] could be used in drug screens against axenic amastigotes
and Leishmania infected human macrophages for the discovery of novel effective
compounds .
1.3.6 Inhibition of Leishmania mexicana by natural products
Aims and Objectives
1. Investigative natural products as anti-leishmanials by fractionation
2. In vitro testing of natural compounds against axenic L. mexicana amastigotes,
cytotoxicity testing against human macrophages and L. mexicana infected
human macrophages.
3. Explore L. mexicana amastigote lipid metabolomics for hit compounds, and
putative target validation.
Chapter 2
Materials and Methods
2.1 Sequence analysis
DNA and protein sequences for T. gondii were obtained from (www.toxodb.org) us-
ing the following reference numbers: ID TGGT1_234570, TGGT1_273740, TGGT1_201850,
TGGT1_231870. Sequence alignments were carried out using ClusterW2 (Clus-
terW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). Cloning strategies used ApE
A plasmid Editor by M. Wayne Davis and Conversion Script by T.P. Breckon (see
Appendix A)
2.2 Materials
2.2.1 Growth media, Culture media, antibiotics and inducer
For bacterial growth all liquid and solid Lysogay Broth, Miller’s LB Broth (LB)
media (Sigma-Aldrich, L3522) was made using distilled water and autoclaved at
121°C for 15 min. For broth, 25g LB powder per litre of water was used, while semi-
solid LB for plates contained 25g LB and 15g Agar (Sigma-Aldrich, A9539). Both
media were supplemented with relevant antibiotic where applicable. For long-term
storage cultures were mixed to give 50% (v/v) glycerol and kept at -80%.
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Mammalian cell line and T. gondii, were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) high glucose without L-glutamine (Sigma-Aldrich, D5671) sup-
plemented with 10% Foetal Bovine Serum (FBS) (Gibco, 10270) 4 mM L-glutamine
(Sigma-Aldrich, G7513) and 42 mM Gentamicin (Gibco 15710-049). 50% (v/v) FBS
20% (v/v) DMSO and 30% (v/v) DMEM was used to store cell lines and T. gondii
infected cells at -150°C.
Antibiotics: 50 mg/mL stocks of Gentamicin (Gibco, 15710-049), Kanamycin (Sigma-
Aldrich, K1377) and Ampicillin (Sigma-Aldrich, A0166) were made in distilled wa-
ter, filter sterilised, aliquoted and stored at -20°C and used within a month.
Inducer, Isopropyl b-D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich, I5502) was
made in distilled water to a 1 M concentration and stored at -20°C.
2.2.2 Buffers
Buffers used are listed below;
Buffer A: 100 mMKH2PO4(Sigma-Aldrich, RES20760-A7), 5 mM 2-mercaptoethanol
(Sigma-Aldrich, M6250) pH 7.4
Glutathione-Buffer A: Glutathione column elution buffer consited of Buffer A
with 20 mM reduced glutathione (Sigma-Aldrich, G4251) pH7.4
Storage buffer A: Buffer A and 50% (v/v) glycerol.
Nickel Elution-Buffer A: Nickel column elution buffer (Nickel Elution-Buffer
A): Buffer A and 250 mM imidazole (Sigma-Aldrich, I5513) pH7.4
Buffer B: (SDS-PAGE running buffer): 10 X SDS-PAGE Running Buffer (1 L)
contained 144 g glycine (Sigma-Aldrich, G8898) 30.2 g Tris (Sigma-Aldrich, T1503),
then for 1 X running buffer 100 ml of 10 X to 900 ml distilled water was used. The
buffer was used at concentration for gel electrophoresis.
Buffer C: For T .gondii transfection; Cytomix (Electroporation buffer): 120
mM KCl (Sigma-Aldrich, P9333) 0.15 mM CaCl2 (Sigma-Aldrich, C1016 ) 10 mM
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KH2PO4(Sigma-Aldrich, RES20760-A7), pH 7.6 25 mM HEPES (Sigma-Aldrich,
H3375) pH 7.6, 2 mM EGTA , pH 7.6, 5 mM MgCl2 ( Sigma-Aldrich, M8266)
adjusted with KOH (Sigma-Aldrich, P5958) to pH 7.6
LiT/PEG mix: 40% (w/v) PEG 3350 in LiT solution (LiT = 100 mM LiOAc and
10 mM Tris-HCL pH 7.4)
2.2.3 Bacterial strains, Toxoplasma gondii strain and cell
lines
All plasmids, cell lines bacterial and parasitic strains are listed in Table 2.1, Table
2.2 and Table 2.3
Table 2.1: E. coli strains used in this study
Strain Genotype Source
DH5a (origin of
strain was
developed by D.
Hanahan) [72]
F- F80lacZDM15 D(lacZYA-argF)
U169 recA1 endA1 hsdR17(rk-,
mk+) phoA supE44 thi-1 gyrA96
relA1 l-
Invitrogen,
182163-012
BL21 (DE3)
Rosetta (Brussels
strain of E. coli
by Delbrück and
Luria) [73]
huA2 [lon] ompT gal (l DE3)
[dcm]  hsdS l DE3 = l sBamHIo
 EcoRI-B int::(lacI::PlacUV5::T7
gene1) i21  nin5
NEB, C2527I
StellarTM
Competent Cells
F–, endA1, supE44, thi-1, recA1,
relA1, gyrA96, phoA, F80d lacZD
M15, D (lacZYA - argF) U169, D
(mrr - hsdRMS - mcrBC), DmcrA,
l–
Clontech, 638909
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Table 2.2: Parasite Strains and cell lines used in this study
Type Description Source
RH T. gondii (ATCC® 50174D™) Organism: T.
gondii
Prof. Markus Messiner
M379 L. mexicana (ATCC® 50156™) Organism: L.
mexicana
Dr. Paul Denny
HFF cells (ATCC® SCRC-1041™) Organism: Homo
sapiens, human ,
Cell Type:
Fibroblast ,
Tissue: Skin;
foreskin
Prof. Markus Meissner
Macrophage RAW 264.7 (ATCC® TIB-71™) Organism: Mus
musculus , mouse,
Cell Type:
Macrophage
Dr. Paul Denny
Fibroblast GM5756 Organism: Homo
sapiens, human ,
Cell Type:
Fibroblast ,
Tissue:
Prof. Ralf Ederman
Vero Cells Organism:
Cercopithecus
aethiops ,Tissue:
kidney
Dr. Paul Denny
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Table 2.3: Plasmids for protein expression and localisation
Plasmid Description Source
TgSCP2pUC57 TGSCP2_TGGT1
_29097 1878 bp in
pUC57
Ampr
GenScript
TUB8
mycGFPmyoATy-
HX
T.gondii transfection
vector with GFP tag
and TUB8 promoter
Ampr
Prof. M Meissner
(Glasgow
University)
pFA6a-GFP-eSKL T.gondii transfection
vector with GFP tag
and TEF promoter
Kanr
Dr Lilach
Sheiner
(Glasgow
University)
TgSCP2TUB8
mycGFPmyoATy-
HX
TGSCP2_TGGT1
_29097 in T.gondii
transfection vector with
GFP tag and TUB8
promoter
Ampr
In House (A J
Mbekeani)
pETM-30 Expression vector with
His tag, GST tag, TEV
protease cleavage site,
Kanr
Dr. Gunter Stier
Heidelberg
(www.embl.de)
pETM-30-TgSCP2 TgSCP2 gene in
expression vector with
His tag, GST tag, TEV
protease cleavage site,
Kanr
GenScript
pETM-30-TgPex5 TgPEX5 gene in
expression vector with
His tag, GST tag, TEV
protease cleavage site,
Kanr
GenScript
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2.3 Protein ExpressionTgPex5c-terminal andTgSCP2PTS1
Clones of TgPex5c-terminal and TgSCP2PTS1were obtained from pETM-30-TgSCP2
and pETM-30-TgPex5 plasmids manufactured and supplied by GenScript. These
plasmids were subsequently used in protein expression. When plasmid DNA was
required, a mini-prep was performed using QIAprep Spin Mini-prep following man-
ufactures guidelines (Qiagen, ID 27104).
2.3.1 Bacterial transformation
Transformation of BL21 with plasmid DNA allowed the expression of TgPex5C-TERMINAL
and TgSCP2PTS1 proteins. Competent BL21 (DE3) cells were thawed on ice and 1-
100 ng DNA added, then incubated at 42°C for 30 seconds, before returning to ice
for 2 minutes. Growth media was then added followed by a further 1 hour incuba-
tion at 37°C. A porportion of the culture was then spread onto agar plate, carrying
the relevant selective antibiotic. Transformed colonies were chosen and used to in-
oculate LB broth supplemented with antibiotic and used to make glycerol stocks.
Both DH5a glycerol stocks for future cloning experiments and BL21 stocks for large
scale protein expression were generated.
2.3.2 TgPex5c-terminal and TgSCP2PTS1 expression & purifica-
tion
Expression of TgPex5C-TERMINAL and TgSCP2PTS1 recombinant proteins in BL21 cells
was scaled up starting form a single colony streaked from glycerol stocks. 20ml of
starting culture of BL21 pETM-30-TgSCP2 or pETM-30-TgPex5 was used to inocu-
late 1 litre of LB containing 50mM Tris-hydrochloride (Sigma-Aldrich, 10812846001
ROCHE), supplemented with 1% (w/v) glucose (Sigma-Aldrich, G8270) and 50
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mg/ml kanamycin (Sigma-Aldrich, K1377) at pH 7.5. Culture flasks were placed at
37°C in a shaking incubator at 150 rpm. When an OD600nm~0.5-0.8, was achieved,
the temperature was reduced to 20°C for 1 hour, then protein expression induced
with 0.5 mM IPTG (Sigma-Aldrich, I5502) and grown overnight at 30°C. Cultures
were then centrifuged at 4000 rpm for 35 min at 4°C and re-suspend in 35 ml of
Buffer A. Cell pellets were flash frozen in liquid nitrogen and stored at -80°C until
needed.
For protein purification the process, TgPex5C-TERMINALand TgSCP2PTS1 Stored
frozen pellets from overexpressed cultures of TgPex5C-TERMINALand TgSCP2PTS1 were
thawed and re-suspended in 15 mL Nickel Elution-Buffer A supplemented with an
EDTA-free complete protease inhibitor cocktail tablet (Sigma-Aldrich, 04693159001
ROCHE) and 1 mg/mL lysozyme (Sigma-Aldrich, L1667) 1 mg DNase I and 1 mg
RNase A. Cells were then sonicated using a Bandelin Electronic UW2200 sonica-
tor for 5 x 1 min with 15 second pulses. The lysate was kept on ice during and
after sonication and centrifuged at 40 000 rpm (JLA 8.100) for 45 min, at 4°C.
The supernatant was filtered through a 0.45 mm filter [40, 74]and the soluble frac-
tions containing fusion protein were subjected to digestion by TEV protease at 4°C
overnight. This solution was passed through a GSTrap column and bound proteins
eluted in Buffer A and glutathione. The products at each stage of the purification
were analysed by SDS-PAGE [40].
2.3.3 Glutathione affinity chromatography
The filtered supernatant was applied to a 1 mL glutathione Sepharose 4B resin
column (GSTrap) using a peristaltic pump (GE, 17-5130-01), pre- equilibrated in
Nickel Elution-Buffer A. This GSTrap column was washed with Nickel Elution-Buffer
A and eluted with Glutathione-Buffer A [40].
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2.3.4 Tag Cleavage, dialysis and protein concentration
The eluted products containing fusion protein were then cleaved with TEV protease
(Sigma-Aldrich, T4455) in accordance with the manufacture’s instructions. In pi-
lot studies protein precipitation occurred upon cleavage with TEV at 30°C for 1
hour. Further studies found that precipitation was prevented by cleavage at 4°C
overnight. Dialysis from Nickel Elution-Buffer A supplemented with 20 mM re-
duced glutathione into Nickel Elution-Buffer A was performed after samples had
been cleaved with TEV. The buffer exchange was through dialysis tubing (10 kDa
molecular weight cut-off (MWCO), and was carried out for 3 hours at 4°C to remove
the cleaved tag. Following dialysis, samples TgPex5C-TERMINAL and TgSCP2PTS1were
concentrated using Merck Millipore filters, 10kDa MWCO) [40].
2.3.5 Nickel affinity chromatography
TEV-cleaved products were next applied to a column Ni-NTA column, pre-equilibrated
in Buffer A. The flow-through was retained proteins which contained the cleaved
TgPex5C-TERMINAL and TgSCP2PTS1while His6-TEV and His6-GST remained bound
to the Ni-NTA column (GE Healthcare). Nickel Elution-Buffer A was then used
to remove the His-tagged peptides [40]. Following manufactuers guidelines SDS-
PAGE equipment and protocols were adopted during protein expression and purifi-
cation stages. For the polyacrylamide gel; 30% acrylamide, resolving buffer, stacking
buffer, Ammonium persulfate (APS) 10% w/v (Sigma-Aldrich A3678) and TEMED
(Sigma-Aldrich T9281) were used and electrophoresed in Buffer B at 200 V for 60
minutes [74].
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2.4 In vitro localisation of TgSCP2 and enhanced
PTS1-Tagged GFP in Toxoplasma gondii
TgSCP2 and enhanced PTS1-Tagged GFP cDNA was cloned into independent plas-
mid vector and later transfected into T. gondii and used to infect confluent HFF-1
cells, prior to fixation and antibody staining [24].
2.4.1 Cloning TgSCP2COMPLETE into TUB8mycGFPmyoATy-HX
and GFP-enhanced(e)PTS1 into pFA6a-GFP-eSKL
Cloning of respective PCR fragments was carried out using two different cloning
methods. For TgSCP2COMPLETE into TUB8mycGFPmyoATy-HX, The Clontech®
Laboratories, Inc. In-Fusion®HD Cloning Kit was used, while the GFP-enhanced(e)PTS1
into pFA6a-GFP-eSKL used standard cloning techniques as described below.
2.4.1.1 Cloning TgSCP2COMPLETE into TUB8mycGFPmyoATy-HX
As previously described [24]the complete cDNA of TgSCP2 was cloned into the plas-
mid vector using the entire sequence of TgSCP2 (TGSCP2_TGGT1_29097 Length:
1878 bp), using InFusionTM and following the manufactuers guidelines . This tech-
nique allowed directional cloning of PCR fragment into our linearized vector with
>95% cloning efficiency. Here, TgSCP2 was amplified from cDNA purchased from
Genscript TgSCP2pUC57 by the primer pair FW primer SCP2 TUB8 and RV primer
SCP2 TUB8 (Table 2.4). Amplified fragments of ~1.9 KDa for TgSCP2 were cloned
into TUB8mycGFPmyoATy-HX. Sucessful insertion of TgSCP2 was confirmed by
restriction site mapping using EcoRI and BamHI in TgSCP2 and DNA sequenced
by Eurofins show in Appendix A. The new construct TUB8mycGFPmyoATy-HX-
TgSCP2 was introduced into StellarTM competent cells by transformation . Trans-
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formant colonies were selected and used to inoculate liquid LB supplemented with
appropriate antibiotic and used to make glycerol stocks. Mini-prep plasmid DNA
made using QIAprep Spin Mini-prep method was subsequently used in transient
transfection.
2.4.1.2 Cloning GFP-enhanced(e)PTS1 into pFA6a-GFP-eSKL
The GFP-enhanced(e)PTS1 cassette was amplified from the vector pFA6a-GFP-
eSKL [75] using the primer pair FW primer (e)PTS1 pFA6a and RV primer (e)PTS1
pFA6a (Table 2.4). The PCR product was inserted into pTUB8-myc-GFP to form
pTUB8-GFP-ePTS1.
2.4.2 Maintenance and culture of HFF-1 and T. gondii
The maintenance and culture of a variety of T. gondii strains on HFF-1 cells for the
various experiments used in this project followed perviously described protocols as
described and detailed below [76,77].
2.4.2.1 Maintenance and culture of HFF-1 and T. gondii Type I (RH
and RH-HX-KO-YFP2-DHFR)
RH T. gondii wild-type and RH-HX-KO-YFP2-DHFR parasites were grown on
human foreskin fibroblasts HFF-1 (ATCC SCRC, 1041) in an incubator at 37 ￿.
HFF-cells were thawed at 37 ￿, 5%,CO2 HFF-1 in DMEM (Sigma-Aldrich, D5671)
supplemented with 10% FBS (Gibco, 10270) 4 mM L-glutamine, 42 mM Gentamicin
HFFs and incubated overnight. After the addition on trypsin, cells were seeded into
other flasks and reached confluency in 2-3 days. Thereafter, 1:4 split was carried out
every week to maintain the HFF-1 culture. RH T. gondii or RH-HX-KO-YFP2-
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DHFR parasites were then used to infect confluent HFF-1 cells. These tachyzoite
cultures were grown continuously at 37 ￿ until HFF-1 cells lysed and extracellular
parasites were present. Extracellular T.gondii were then subcultured onto fresh
HFF-1 for a repeat cycle [76,77].
2.4.2.2 Maintenance and culture of HFF-1 and Toxoplasma gondii Type
II (Pru-GRA2-GFP-DHFR )
Pru-GRA2-GFP-DHFR T. gondii parasites were also grown on human foreskin
fibroblasts HFF-1 using the same conditions as the RH strain. Once tachyzoite
culture had been established, parasites were grown continuously under the same
conditions. If encysted bradyzoites were required then once tachyzoites had formed
plaques, media DMEM supplemented with 10% FBS 4 mM L-glutamine 42 mM
Gentamicin at pH8 was used to allow the transformation of tachyzoites to encysted
bradyzoites over a 24 hour period as described by [78].
2.4.3 Toxoplasma gondii transient transfections
Transient transfection followed the protocols described by Soldati and Boothroyd
[39].
2.4.3.1 TUB8mycGFPmyoATy-HX-TgSCP2 transfection of Toxoplasma
DNA TUB8mycGFPmyoATy-HX-TgSCP2 plasmid DNA for transfection was pre-
pared using ice cold 100% EtOH 1% NaAceate and incubated at -20ºC overnight,
then centrifuged at 14 000 rpm for 30 min followed by two washes with 70% ethanol.
The supernatant was removed and the pellet left to dry for 15 min. Between 30-60
mg of DNA was then used for T. gondii transfection. Freshly lysed extracellular T.
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gondii approximately 107 extracellular parasites from HFF’s, were centrifuged at
1000 rpm at 4ºC for 10 min. The supernatant was discarded and cells washed with
Cytomix and centrifuged for 5 min at 1200 rpm. Plasmid DNA (approximately 60
µg) mixed with the resuspended parasite cell pellet in cytomix containing 100 mM
ATP and 100 mM GSH, before adding to an electroporation cuvette. For electro-
poration, in a Bio-Rad, Gene Pulser Xcell™ Electroporation Systems, settings were
“square wave protocol #3 Voltage : 1700 V Pulse Length: 0.2 ms # of pulses: 2
interval: 5 sec 4 mm cuvette gap.” Transfected parasites were used to inoculate a
dish containing confluent HFF cells grown on coverslips..
2.4.3.2 ePTS1-GFP transfection into Toxoplasma
For the ePTS1-GFP transfection, after the amplicon was purified, the PCR product
was cloned into pTUB8-myc-GFP to form pTUB8-GFP-ePTS1. The Toxoplasma
RH strain were transfected with pTUB8-GFP-ePTS1 and used to infect HFF cells
cultured on glass coverslips as described above.
2.4.4 Immunofluorescence assay for Toxoplasma gondii trans-
fection
For the immunofluorescence assay (IFA), HFF cells grown on coverslips were in-
oculated with TUB8mycGFPmyoATy-HX-TgSCP2 transfected T. gondii and En-
hanced PTS1-Tagged GFP transformed Toxoplasma parasites [77, 79].
2.4.4.1 TUB8mycGFPmyoATy-HX-TgSCP2 in Toxoplasma
For TUB8mycGFPmyoATy-HX-TgSCP2 in Toxoplasma, cells were fixed with 4%
(w/v) paraformaldehyde (Sigma-Aldrich, P6148) in phosphate buffered saline (PBS)
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(Sigma-Aldrich, P5493) for 20 min at room temperature at 24 hrs and 48 hrs. Fixed
cells were permeabilized and blocked using 0.2% Triton-X100 (Sigma-Aldrich X100),
2% bovine serum albumein (BSA) (Sigma-Aldrich, 05470) in PBS and stained.
DAPI (ThermoFisher Scientific) and primary antibodies (anti-IMC1 and anti-GFP;
Roche) diluted 1:1000, were used in study. Cells were incubated for 1 hour at room
temperature then washed three times, and incubated with Alexa488 goat anti-mouse
and Alexa594 goat anti-rabbit (ThermoFisher Scientific) for 45 min at room tem-
perature, in a mixture of PBS with 0.02% Triton-X-100 and 2% BSA.
2.4.4.2 Enhanced PTS1-Tagged GFP in Toxoplasma
Similarly enhanced PTS1-Tagged GFP in Toxoplasma, after 24 h, cells were also
fixed with 4% paraformaldehyde at room temperature for 20 minutes and washed in
PBS, before permeabilization and blocking in PBS 0.02% Triton-X-100/2% BSA for
a further 20 min. Cells were then incubated for 1 hour at room temperature with
the primary antibodies anti-IMC1 and anti-GFP diluted 1:1000, washed three times,
and incubated with Alexa488 goat anti-mouse and Alexa594 goat anti-rabbit for 45
min, also at room temperature and in PBS 0.02%, Triton-X-100 and 2% BSA [80].
2.4.5 Microscopy for transfected Toxoplasma gondii para-
sites.
Super-resolution microscopy was used to visualise antibody stained parasites. Using
an ELYRA S.1 microscope (Zeiss) equipped with a plan apochromat 63×, 1.4 NA
oil immersion lens. Coverslips with transfected parasites were used for imaging and
photographs recorded with a CoolSNAP HQ camera (Photometrics) and processed
using ZEN Black software (Zeiss) and analysed using Fiji [81].
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2.5 TgPex5 yeast complementation
Various yeast complementation strategies that allowed quantitative and qualita-
tive analysis are described below and were used in determining the functionality of
TgPex5 and TgPex7.
2.5.1 Cloning of TgPex5 into yeast plasmid vector pIRES2-
EGFP-SKL
For cloning, complete cDNA of TgPex5 into plasmid vector, we used the entire se-
quence of TgPex5 (TGGT1_231870 Length: 2679 bp). Using the Infusion cloning
kit and following manufactuers guidelines (Clontech® Laboratories, Inc. In-Fusion®
HD Cloning Kit User Manual), TgPex5 was amplified from genomic DNA by primer
pairs as shown in Table 2.4. An amplified fragments of approximately 2.7 Kbp for
TgPex5 was cloned into the yeast plasmid vector pIRES2-EGFP-SKL using infu-
sion cloning. pIRES2-EGFP-SKL-TgPex5 plasmids introduced transformed into
StellarTM competent cells . Transformed colonies were selected and used to inocu-
late liquid LB supplemented with appropriate antibiotic and used to make glycerol
stocks.
2.5.2 Culture and maintenance of yeast strains
The Saccharomyces cerevisiae strains used were UTL-7 (wild-type), and UTL-7DPex5
all grown at 30°C in YPD medium or YPD plates containing 2% glucose (Sigma-
Aldrich, G7021), 2% peptone (Sigma-Aldrich, 19942) and 1% yeast extract (Sigma-
Aldrich, 70161) as previously described [82].
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2.5.3 Transfection of pIRES2-EGFP-SKL-TgPex5 into WT
and mutant yeast
The transfection of pIRES2-EGFP-SKL-TgPex5 into UTL-7, and UTL-7DPex5
(null mutant) involved several stages as described [83]. First, TgPex5-pIRES2-
EGFP-SKL DNA was isolated using a QIAprep Spin Mini-prep kit. For transfec-
tion all strains were grown as described in subsection 2.5.2 and harvested in 1.5 mL
microcentrifuge tubes. 1-10 mg plasmid DNA was then added to Herring/salmon
sperm DNA (already denatured at 95￿ for 5 minutes) and LiT/PEG mix ( 2.2.2
) and placed on a shaker for 15 minutes at room temperature. Samples were in-
cubated for 12 minutes at 42￿ and centrifuged at 14 000 rpm for 5-10 seconds,
supernatant removed and cells resuspended in 50 ml of sterile water before plating
onto -URA plates to be used in spot test, immunoflorecence assay and oleate yeast
growth assays.
2.5.4 Spot test for transfected TgPex5
Transfected colonies were picked from -URA plates (section 2.5.3 ) and were used to
inoculate 10 mL of 0.3% glucose medium and grown overnight. 1 mL of culture was
then spun, supernatant removed, and the pellet re-suspended in 1 mL sterile water.
The pellet was washed 3 times with sterile water before OD600nm measurement.
Optical density measurements involved 100 ml cells + 900 mL sterile water. Once an
OD600nm between 0.2 - 0.5 was achieved, serial dilutions of transfected yeast and
control yeast cultures were made using a 1:10 dilution. 1.0 ml of each of the serial
dilutions was pipetted onto glucose-URA and olate-URA plates. Controls on the
plates were also added and included serial dilutions of 1.0 ml of UTL-7DPex5 and
the empty plasmid vector. Plates were incubated at 30°C for 3 to 4 days before
image capture by DSLR ( Digital Single Lens Reflex) as described [84].
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2.5.5 Oleate liquid culture growth assay of transfected TgPex5
The culture from subsection 2.5.4 was used to inoculate 10 mL of 0.3% glucose
medium and grown overnight. 1 mL of culture was then centrifuged, and the pellet
re-suspended in 1 mL sterile water. The 100 mL pellet was washed 3 times with
sterile water to remove glucose before being resuspended in 900 mL of sterile water.
Once an OD600 nm of less than 0.1 was achieved, the 1 ml volume was used to
inoculate 10 ml of oleate media and incubated at 30￿ for 24 hours.
2.5.6 Yeast immunoflorecence assay of transfected UTL-7,
and UTL-7DPex5
For the immunofluorescence assay (IFA), cells from the remaining serial dilutions
(2.5.4) were fixed with 4% w/v paraformaldehyde (Sigma-Aldrich, P6148) in phos-
phate buffered saline (PBS) for 20 min at room temperature. Cells were then per-
meabilized and blocked using 0.2% Triton-X100 , 2% bovine serum albumen in PBS.
Cells were DAPI stained and visualised using a wide-field fluorescence microscope
(Zeiss Axiovision (version 4.6.3) microscope and 1300Y digital camera (Roper Scien-
tific RTE) . The GFP signal was visualized using a 450-490 nm band pass excitation
filter, a 510 nm dichromatic mirror and a 515-565 nm band pass emission filter.
2.6 TgPex5 complementation of human fibroblasts
The experiments described below used in determining the functionality of TgPex5
in human fibroblasts.
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2.6.1 Cloning of TgPex5 into human plasmid vector pRS416-
WT
The cloning of complete cDNA of TgPex5 into pRS416-WT using the entire sequence
of TgPex5 (TGGT1_231870 Length: 2679 bp) we used InFusionTM. Both TgPex5
was amplified from genomic DNA by primers pairs as shown in Table 2.4. Ampli-
fied fragments of ~ 2.7 Kbp for TgPex5 was cloned into human plasmid pRS416-
WT. Following manufacturers guidelines pRS416-WT-TgPex5 was transformed into
StellarTM Competent Cells . Transformant colonies were selected and used to in-
oculate liquid LB supplemented with appropriate antibiotic and when required, a
plasmid mini-prep prepared as stated previously.
2.6.2 Maintenance and culture of wild-type and mutant fi-
broblasts
GM5756 (wild-type) and, DPex5 GM5756 (mutant), were cultured and maintained
at 37￿, in a 5% CO2 incubator. Cryo-preserved WT-human and mutant fibroblasts
containing DMSO, were thawed at 37 ￿ and added to DMEM supplemented with
10% FBS 4 mM L-Glutamine, 1% penicillin/streptomycin (Sigma-Aldrich, P4333)
and incubated overnight. The following day cells are washed once to remove DMSO
and reached 70% confluency between 3 to 4 days. Trypsin (Sigma-Aldrich, T1426)
was used to detach cells which were then seeded into other flasks, until they reached
70% confluency over a 2-3 day period. Thereafter, a 1:3 split was carried out every
week to continue fibroblast culture. These were then used in transformations.
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2.6.3 Transfection of TgPex5-pRS416-WT into fibroblasts
Plasmid DNA TgPex5-pRS416-WT and control plasmids were used in the transfec-
tion of wild-type and null mutant fibroblasts. WT-GM5756, and DPex5 GM5756,
and fibroblasts were grown to 70% confluency, and 1.5 x 104cells dispensed onto
coverslips. After 24 hrs, fibroblasts at 70% confluency were transfected following
the X-tremeGENE 9 DNA transfection Reagent protocol (Roche) and incubated for
72 hrs ·
2.6.4 Transfected GM5756 and DPex5GM5756 immunoflo-
recence assay
For the immunofluorescence assay (IFA), cells were washed 3 times with PBS and
fixed with formaldehyde (Sigma-Aldrich, F8775) for 20 min at room temperature.
Fixed cells were permeabilized and blocked using 0.2% Triton-X100, 2% BSA (Sigma-
Aldrich, 05470) in PBS and stained accordingly as before with, DAPI, antibodies
and anti-GFP. For imaging wide-field fluorescence microscopy was used, (Zeiss Ax-
iovision (version 4.6.3)) and a 1300Y digital camera (Roper Scientific RTE) and the
GFP. GFP signal was visualized as before.
2.7 Screen of natural compounds against Leishma-
nia mexicana
The in vitro screen of test compounds from Hypha Drug Discovery Ltd, against
L. mexicana M379 amastigotes used three assays: an axenic assay, cytotoxicity
involving a RAW 264.7 human macrophages and L. mexicana M379 amastigotes
and RAW 264.7 macrophage infection assay.
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2.7.1 HDLSX library generation and format
This was carried out by Hypha Discovery
HDLSX library generation and format Scale-up fermentations of fungi selected
for inclusion in the HDLSX library were obtained in multiple shake flasks (each
250 mL Erlenmeyer flask containing 100 mL Leatham’s medium, contents per litre
of water: D-Glucose (25.00 g), L(+)-glutamic acid monosodium salt monohydrate
(3.20 g), KH2PO4 (2.00 g), MgSO4.7H2O (2.00 g), mineral solution (10 mL), trace
element solution (1.0 mL), vitamin solution (1.0 mL) and 1% aqueous salicylic acid
(0.10 mL)) to a total volume of 1-5 L. The fermentations were harvested after the
same period of time that yielded the original activity of interest and this could
vary from as little as 3 to as many as 100 hundred days. Aqueous broth actives
were harvested by various methods depending on the polarities of the components
of interest including extraction with ethyl acetate or capture using Diaion HP20
resin and elution with methanol/acetonitrile. Biomass actives were extracted using
methanol-acetone (1:1). The extracts were concentrated to dryness for storage. The
extracts were weighed and portions stored in 96-well blocks as 10 mg/mL solutions
in DMSO.
2.7.2 Assay-guided Purification
This was carried out by Hypha Discovery
Preliminary small-scale activity-guided purification studies on hits from 12 or-
ganisms that showed promising antiparasitic activity profiles (EC50< 1mg/mL; ther-
apeutic index >100) were conducted using semi-preparative HPLC approaches as
follows: extract aliquots (0.9 mL) were chromatographed by reversed phase HPLC
on an Xbridge Prep Phenyl 5 mm OBD column (19 mm x 100 mm) with a guard col-
umn (19 mm x 10 mm), using gradient elution of 10-100% acetonitrile in water in the
presence of 0.1% formic acid over 8 min, held at 100% acetonitrile for 3 min before
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returning to starting conditions over 1 min at a flow rate of 17 mL/min. 24 fractions
were collected for each fractionation and concentrated to dryness in a Genevac HT12
centrifugal evaporator. The resulting dried fractions were re-dissolved in DMSO-
MeOH (3:1, 0.45 mL) and aliquots (25 mL) transferred to 96 well microtitre plates,
lyophilised for shipping. Analysis of active fractions by HPLC-mass spectrometry
employing an orthogonal reversed phase HPLC-MS method was conducted on a
SymmetryShield RP8 column (3.5 µm; 4.6 mm x 75 mm) eluted with a linear gradi-
ent of 10-95% MeCN in water, containing 10 mM ammonium formate + 0.1% formic
acid, at a flow rate of 1 mL/min, held at 95% MeCN for 1.0 min before returning
to initial conditions over 0.5min; total run time 12 min. UV-visible spectra were ac-
quired using a Waters 2996 photodiode array detector and positive and negative ion
electrospray mass spectra were acquired using a Waters Acquity SQ detector. Puta-
tive molecular weights, UV-Visible maxima and producing organism taxonomic data
were used to search two natural products databases to identify known compounds,
namely Antibase and the Chapman and Hall Dictionary of Natural Products. Spe-
cific chromatographic methods were then developed for the most promising active
primary fractions to separate and resolve their constituent components/HPLC peaks
using a reversed phase column chemistry orthogonal to that used for the primary
fractionation step (usually SymmetryShield RP8). The primary fraction was then
fractionated on the semi-preparative scale and individual HPLC peaks collected into
secondary fractions that were concentrated to dryness, re-dissolved and shipped for
assay as described above.
2.7.3 Scale-up Purification and Structure Elucidation
This was carried out by Hypha Discovery
The target compounds were purified by preparative HPLC methods scaled-up
from the purification methods developed from the small-scale assay guided purifi-
2.7. Screen of natural compounds against Leishmania mexicana 55
cation investigations. HD871-1 was purified from the Diaion HP20 extract of a 5
L fermentation of Marasmius sp. HFN871. The extract was first chromatographed
by preparative HPLC on a Waters Nova-Pak C18 column (40 x 100 mm with a
40 x 10 mm guard column) eluted with a gradient increasing linearly from 10-95%
acetonitrile in water containing 0.1% formic acid over a period of eight minutes at a
flow rate of 50 mL/minute. HPLC was used to check for the presence of the target
metabolite with MH+ at m/z 263 and this was present in fractions eluting between
4.5 and 5.5 minutes. These were combined and further purified by semi-preparative
HPLC on a Waters Atlantis T3 ODS column (10 x 250 mm) eluted isocratically
with 45% aqueous acetonitrile containing 0.1% formic acid at a flow rate of 4.6
mL/minute. HPLC-MS analysis showed that the compound of interest was present
in fractions eluting from 8-9 minutes. A final purification step was achieved by semi-
preparative HPLC on a Waters X-Select C18 column (19 x 100 mm with a 19 x 10
mm guard column) eluted with a linear gradient increasing from 25-30% aqueous
acetonitrile containing 0.1% formic acid over a period of fourteen minutes at a flow
rate of 20 mL/minute. The peak eluting at 10 minutes was collected and concen-
trated to dryness to yield pure HD871-1 (6.9 mg) as a colorless residue. 1H and
13C NMR spectra were acquired at 500 MHz and 125 MHz, respectively, at 298K
in DMSO-d6, on a Bruker AVANCE III 500 MHz NMR spectrometer at the Uni-
versity of Surrey, Guildford, UK. Datasets for structure elucidation included COSY,
HSQC, HMBC and NOESY spectra, which were interpreted at Hypha Discovery
using Mestrenova software. High resolution mass spectrometry was conducted on a
Bruker micrOTOF-Q instrument.
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2.7.4 Maintenance and cell culture of Leishmania mexicana
M379 amastigotes
L. mexicana M379 amastigotes parasites were maintained, in Schneider’s Insect
medium (Sigma-Aldrich, S0146) supplemented with 15% FBS and 1% penicillin/streptomycin
pH 7 (SIM15) and incubated at 26￿. After 3 days procyclic promastigotes were cen-
trifuged at 2000 rpm for 10 mins and re-suspended in Schneider’s Insect medium
supplemented with 20% FBS and 1% penicillin/streptomycin at pH 5.5 (SIM20) to a
concentration of 5 x 105 parasites/mL. After 6 days incubation at 26￿ the metacyclic
forms were then inoculated into fresh SIM20 at 5 x 107 parasites/mL and incubated
at 32￿ for a further 5 to 7 minutes for transformation into amastigotes to be used
in axenic assays (subsection 2.7.6) and infection assays (subsection 2.7.8) [85,86].
2.7.5 Maintenance and culture of RAW 264.7 murine macrophages
Murine macrophages (Mus musculus leukaemia virus transformed macrophage (RAW267.4)
cells (ATCC TIB-71) are an immortal cell line frequently used because it is ro-
bust and gives high differentiation and reproducible proliferation. RAW 264.7
macrophages were cultured and maintained at 37￿ at 5% CO2 . Cryo-preserved
RAW 264.7 were thawed at 37￿ and added to DMEM supplemented with 10% FBS
and 1% penicillin/streptomycin and grown overnight as previously described [85] .
DMSO was removed the following day and cells reached 80% confluency between 3 to
4 days. For sub-culture cells were scraped and seeded into other flasks and reach con-
fluency in 2-3 days. A 1:4 split was carried out every week to continue macrophage
culture and counted using a Neubauer Improved Haemocytometer. These were used
in cytotoxicity (subsection 2.7.7 ) and infection assays (subsection 2.7.8 ) when
required.
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2.7.6 Axenic Leishmania mexicana M379 amastigotes screen-
ing assay
Axenic amastigotes were cultured as described [85] (subsection 2.7.4) and used in
subsequent axenic L. mexicana M379 EC50 and single point amastigote assays .100
mL of 1 x 106 amastigotes from an axenic culture were seeded onto 96-well flat bot-
tom plates (Fisher-Scientific 10792552). For EC50 assay serial compound dilutions
of eight 3-fold dilution steps covering a range from 100 - 0.04 mg/mL were prepared
in culture media SIM20. For the single point assays 1 mL (unknown conc) of com-
pound/extract was added to 99 mL of SIM20 culture media. 100 mL of each of these
compound preparations were then added to the parasites to give a final parasite con-
centration of 5 x 105 per ml and total volume of 200 mL. 10 mM Amphotericin B was
used as a positive control and 2% DMSO as negative control all prepared in CM. Af-
ter a 24 hour incubation 10 mL of alamarBlue (Invitrogen, DAL1025) was added and
incubated for a further 4 hours before obtaining a fluorescent readout (lex 560 nm,
lem 600 nm) using a plate reader SynergyTM HTX Multi-Mode Microplate Reader
(Biotek 560EX nm/600EM nm) [86, 87]. All experiments were carried out a mini-
mum of three times on separate occasions and in triplicate to ensure a robust data
set.
For the initial screening of the HDLSX library (313 extracts) a dose response
approach was taken, testing was in duplicate against both axenic amastigote L.
mexicana and mammalian cells. The Selectivity Index (SI) was calculated from
these data (EC50 mammalian cells / EC50 L. mexicana). Subsequent fractions were
screened at single concentrations in triplicate against the parasite. Determination of
the EC50 of the identified novel antileishmanials against axenic amastigote L. mexi-
cana was carried out using the same assay in triplicate on three separate occasions.
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2.7.7 Cytotoxicity screen using RAW 264.7 macrophages
Cytotoxicity assays were carried out using RAW 264.7 cultured in culture media
(CM10)composed of DMEM supplemented with 10% FBS , and 1% penicillin/streptomycin
(Sigma-Aldrich, P4333) and incubated at 37￿ at 5% CO2 until they reached 80%
confluency as previously optimised [54]. Once confluency was achieved, macrophages
were seeded at 2.5 x 105 cells mL-1 in culture media (CM) in 96-well flat bottom
plates (Fisher-Scientific 10792552) on day 1. On day 2 CM2 made up of DMEM
(Sigma-Aldrich, D5671) supplemented with 2% FBS (Gibco, 10270), and 1% peni-
cillin/streptomycin (Sigma-Aldrich, P4333) was used to wash macrophages, followed
by the addition of 200 mL/mL of CM2 to each well and incubated for 24 hours. On
day 3, all macrophages were washed 5 times with CM2, before addition of 100 mL of
test compounds/extract (10 mM DMSO stock solutions, serial compound dilutions
of eight 3-fold dilution steps covering a range from 100 - 0.04 mg/mL) and control
solutions (1 mM Cyclohexamide used as a positive control and 2% DMSO as neg-
ative control) all prepared in CM2, then incubated at 37￿ in 5% CO2 . After 24
hour incubation on day 4, 10 mL of alamarBlue was added to each well. A 4 hour
incubation at 37￿, 5% CO2 with alamarBlue (Invitrogen, DAL1025) was followed
by fluorescent (lex 560 nm, lem 600 nm) using a plate reader to determine cell viabil-
ity [87]. All experiments were carried out independently a minimum of three times
and in triplicate data and the raw data used in statistical analysis explained later.
2.7.8 Leishmania mexicana M379 amastigotes and RAW 264.7
macrophage infection assay
For the infection assay as previously described by [54, 86, 87], on day 1, well main-
tained RAW 264.7 macrophages ( 2.7.5 ) were seeded at 2.5 x 105 cells/mL in
CM10 and added to 96-well flat bottom plates (Fisher-Scientific 10792552) incu-
bated for 24 hours at 37ºC, 5% CO2 . On day 2, macrophages were washed with
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CM2 followed by the addition of 1 x 106cells/mL axenic L. mexicana M379 amastig-
otes in CM2 and incubated overnight for 24 hours at 37ºC, 5% CO2 . On day 3,
infected macrophages were inspected under the microscope to ensure infection. Test
compounds in CM2solution from 10 mM DMSO stock solutions were used for se-
rial compound dilutions of eight 3-fold dilution steps covering a range from 100 -
0.04 mg/mL. Control solutions of 1 mM Cyclohexamide and 10 mM Amphotericin
B for uninfected RAW 264.7 macrophages and infected RAW 264.7 macrophages
respectively and 2% DMSO as negative controls were added and plates incubated
for 24 hours at 37ºC, 5% CO2 . On day 4, infected RAW 264.7 macrophages
were washed 5 times with Schneider’s Insect medium (Sigma-Aldrich, S0146) pH 7
(SIM) and inspected under the microscope to ensure the removal of all extracellular
amastigotes. This was then followed by cell lysis using 0.05% v/v for 30 seconds
to lyse RAW 264.7 macrophages before the addition rapid addition of neutralising
solution SIM15. Plates were then incubated at 26 ºC for 48 hours. On day 6, 10
mL of alamarBlue (Invitrogen, DAL1025) was added to each well followed by a 4
hour incubation at 26 ºC and fluorescent readout (lex 560 nm, lem 600 nm) using
plate reader (Biotek 560EX nm / 600EM nm). All experiments were carried out on
three different occasions and in triplicate to ensure a robust data set then raw data
used in statistical analysis to determine EC50 values. The Selectivity Index (SI) was
calculated from these data (EC50 RAW 267.4 / EC50 intracellular L. mexicana).
2.7.9 Statistical analysis
Data were analysed using a macro programmed Excel spreadsheet (Appendix B) and
Graphpad Prism (V 7.0). Sigmoidal curves were plotted to show growth inhibition
against compound concentration and produce EC50 values, Z’ values and standard
deviation were all produced from the dose-response plots.
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2.8 Effect of HD871-1 and HDL871-2 on Leishma-
nia mexicana amastigotes metabolome
Experiments described in this section involved the two hit compounds identified after
the entire screen of 313 natural compounds from Hypha. These two compounds were
used for the metabolomics study.
2.8.1 Half time to cell death assay
The aim of the half time to death assay was to determine the correct concentrations
to be used in the experiment examining the effect of HD871-1 and HD871-2 on L.
mexicana M379 amastigotes metabolome. For this 10 mM stocks of both HD871-1
and HD871-2 were diluted in SIM20 and plated out in triplicate onto sterile 24 well
plates (Nunc) to final concentrations of 10, 5, 2.5, and 1.25 mM. 1 x 107 parasites/mL
final concentration were then added to theses serial dilutions to give a final volume
of 1 mL/well. Plates were then incubated at 32ºC and the number of parasites
examined at four time points 12, 24, 36 and 48 hours by microscopic observation
2.8.2 Cell extraction for Leishmania mexicana M379 amastig-
otes
The optimum time point for cell extraction of the L. mexicana M379 amastigotes
metabolome as determined by the half time to cell death assay (subsection 2.8.1 )
for HD871-1 and HD871-2 was at 10 mM for 36 hours. After 36 hours compound
exposure amastigotes started to die.
2.8.2.1 Seeding Leishmania mexicana M379 amastigotes
L. mexicana M379 amastigotes were cultured as detailed in subsection 2.7.4 to con-
centration of 1 x 108 parasites/mL and were seeded into T75 tissue culture flasks
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(Starsted, 83.3911) at a concentration of 5 x 107parasites/mL in SIM20. Com-
pounds HD871-1 and HD871-2 and negative control DMSO were added to flasks.
Each sample and control were seeded and inoculated with compound or control in
quadruplicate. Flasks were then incubated at 32ºC for 36 hours and amastigotes
counted for metabolic extraction.
2.8.2.2 Leishmania mexicana M379 amastigotes metabolome post-exposure
to HD871-1, HD871-2 and DMSO
For the cell extraction of L. mexicana M379 amastigote metabolome post-exposure to
HD871-1, HD871-2 and DMSO, 5 x 107parasites/mL of each sample in quadruplicate
was harvested by a 15 minute centrifugation at 1430 g and temperature rapidly
reduced by placing samples on dry ice, with intermittent vigorous mixing to avoid
cell lysis. Samples were then maintained at a temperature of 4￿ for the rest of the
protocol. Samples were centrifuged at 1250 g for 10 minutes before supernatants
were removed and pellets resuspended in 1 mL of their residual media. These 1
mL of suspensions were then transferred to 1.5 mL centrifuge tubes and further
centrifuged at 2260 g for a further 10 minutes. Supernatants were removed and
pellets resuspended in PBS for a 10 minute wash at 2260 g. After the PBS wash,
extraction media (chloroform (Sigma-Aldrich, 288306 ):Methanol (Sigma-Aldrich,
322415) : Water) (CMW in a ratio of 1:3:1 v/v/v) was added to the pellets, mixed
and left on a shaker at maximum speed for 1 hour. After incubation, samples were
centrifuged at 18890 g for 10 minutes and the supernatant removed placed in a vial
and sealed with Argon before storing at -80￿ until analysis by mass spectrometry.
[86,88].
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2.8.3 Metabolome analysis
All twelve samples were analysed by liquid chromatography-mass spectrometry (by
Erin Manson, Glasgow Polyomics Research Centre) and evaluated by IDEOM in an
excel template.
Metabolites were extracted and analysed as follows: For LC-MS metabolomic
analyses, samples were first separated using HPLC with a 150 x 4.6 mm ZIC-pHILIC
(Merck) column on UltiMate 3000 RSLC (Thermo Scientific). Mass detection used
an Orbitrap Q-Exactive mass spectrometer (Thermo Fisher) at Glasgow Polyomics,
using positive and negative polarity switching mode, with a 10 mL injection volume
and flow rate of 300 mL/min. 249 authentic standards were included to assist com-
pound identification. Data were processed and analyzed using mzMatch [89] and
IDEOM software [90]. All the MS analyses were performed in at least triplicate.
Exact mass is measured and this is converted, where possible to a formula corre-
sponding to that mass. Screening of a database of metabolites with that formula
then yields a putative identity. Where an authentic standard has a matching mass
and retention time this is taken as a likely hit. Other annotations are tentative
(metabolomics standards initiative level 2, [91] with this data.
2.9 In vitro screen of natural compounds against
Toxoplasma gondii
Two approaches were used for compound screening and involved a screen against
5 compounds and some peroxisome specific inhibitors. The 5 compounds were
screened against both Type I and II T. gondii while the Pex inhibitors were screened
against Type I T. gondii.
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2.9.1 In vitro screen of natural compounds against Toxo-
plasma Type I
As described in subsection 2.4.2.1 cultured HFF cells and extracellular RH-HX-KO-
YFP2 tachyzoites were used in a Toxoplasma susceptibility assay. 1 x 104 cells
per well were seeded onto 96 well microtitre plates (Nunc). HFF cells after an 18
hour incubation at 37￿, 5% CO2 , had the addition of isolated RH-HX-KO-YFP2
tachyzoites at 6250 parasites per well and incubated at under the same conditions for
a further 20 hours. Following incubation test compounds with eight serial dilutions
of 2-fold dilution steps covering a range from 0.04 -10 mg/mL were added.
2.9.2 Optimised in vitro screen of natural compounds against
Toxoplasma Type II
Experiments were previously described [78, 92] in subsection 2.4.2.2 with cultured
HFF cells and extracellular Pru-GRA2-GFP-DHFR tachyzoites used in a Toxo-
plasma bradyzoite susceptibility assay. 1 x 104 cells per well were seeded onto 96
well microtitre plates (Nunc). After an 18 hour incubation at 37￿, 5% CO2 ,HFF
cells had the addition of isolated Pru-GRA2-GFP-DHFR tachyzoites at 6250 para-
sites per well and incubated at 37￿, 5% CO2 for a further 48 hours to allow encysted
bradyzoites to develop. Tachyzoites differentiated to the bradyzoite-like form in HFF
cells via an alkaline shift to pH8. Following incubation, test compounds with eight
serial dilutions of 2-fold dilution steps covering a range from 10 - 0.04 mg/mL were
added.
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2.9.3 In vitro screen of Pex5 and Pex14 inhibitors against
Toxoplasma Type II
HFF cells were seeded at 104 cells per well in a 96 well plate and maintained in
fluorobrite medium. After 18 hours at 37°C, isolated T. gondii tachyzoites were
inoculated into the host cells at 6250 parasites per well, compounds were added
after a further 20 h incubation period, with concentrations starting at 50 mM and
terminating at 0.21 mM via a 3-fold serial dilution. Pyrimethamine at 40 mM acted
as the positive control and DMSO 2.5mM the negative control. Plates were analysed
every 24 hrs post addition of the compounds from 48 to 144 hours, with an excitation
and emission wavelength of 510 nm and 540 nm, respectively. Data was analysed
using GraphPad Prism.
2.9.4 Analysis for both Toxoplasma Type I and Type II
All plates for natural compounds were then read after 3 or 6 days using a Biotek
Synergy H4 plate reader (Excitation 510 nm; Emission 540 nm). While, the plates
for the Pex inhibitors were read every 24 hours post addition of compounds from
48 to 144 hours, with an excitation and emission wavelength of 510 nm and 540 nm
respectively. All graphs plotted in Graphpad Prism V7 to generate IC50 , CI and R
squared values.
Chapter 3
Results: Exploring natural products
as potential anti-leishmanials
This chapter examined the results of a number of anti-leishmania assays used in
the screening of a MycoDiverseTM HDLSX 313 Fungal Extracts library of natural
compounds provided by Hypha DiscoveryLtd. The library consists of approximately
10 000 refined fractions from fermentations of higher fungi which were made using
Hypha’s proprietary technology producing undescribed compounds with very high
structural novelty and low molecular weight (MW <500). In order to assess the
potential use of natural products against cutaneous leishmaniasis (CL), the library
of natural compounds was screened against the mammalian stage of Leishmania
mexicana. This followed a fractionation and scale up of selected hit compounds
and dereplication. From this a novel compound which demonstrated activity in an
infected cell model was discovered.
The research contained in Chapters 3 nd 4 has been published in the International
Journal of Parasitology
Mbekeani, A.J., Jones R.S., Llorens, M.B., Elliot, J., Barrett, M.P., Steele, J.,
Kebede, B., Wrigley, S.K., Evans, L., and Denny, P.W. Mining for natural product
antileishmanials in a fungal extract library.
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3.1 Previous work
Amphotericin B, is a well known natural product used in the treatment of leishmani-
asis, and has paved the way for the research and discovery of new natural products for
the treatment of this disease. Hypha Discovery (http://www.hyphadiscovery.co.uk)
have exploited the wide availability of higher fungal strains by creating a large-
scale extract (HDLSX) library of 1-5 litre volume fermentation extracts from these
fungi. These mushroom-producing basidiomycetes and ascomycetes, have been
under- explored in the field of antiprotozoal drug discovery, including work for
anti-leishmanials. This unique resource has previously been screened against each
other microbial pathogens and human tumour cell lines, showing biological activity
against [93,94]. A total of 313 compounds were screened and followed by a primary,
secondary and tertiary screens carried out by myself and other members within our
lab.
3.2 Primary Screen
A primary screen was carried out on 313 fungal extracts from the HDLSX library
against the mammalian stage of Leishmania mexicana axenic amastigotes using a
protocol for antileishmanial testing from Chadbourne et al. [95]. Extracts with
an Effective Concentration eliciting 50% inhibition of proliferation) (EC50 ) < 0.025
mg/mL were selected. From the 313 extracts, 38 passed the criteria with a selectivity
index (SI) >48 and after the cytotoxicity screening against mammalian cells and for
other intellectual property reasons, there were a final 17 compounds. Replicated
compounds from the Hypha database were removed to leave 12 hits (HDLEX-9, 18,
79, 14, 21, 22, 159, 171, 33, 35, 67, 127) from the primary screen as shown in Table
3.1.
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Compound number Amastigote EC50 mg/ml Vero EC50 mg/mL Selectivity index (SI) SI >48 Selection
HDLSX-171 3.37E-16 >1.33E+00 >3.95E+15 Y Y
HDLSX-106 2.45E-02 1.07E-02 4.38E-01 N N
HDLSX-67 1.31E-04 6.35E-03 4.84E+01 Y Y
HDLSX-33 5.22E-04 >1.33E+00 >2.55E+03 Y Y
HDLSX-134 6.66E-04 3.28E-04 4.92E-01 N N
HDLSX-14 6.84E-04 >1.33E+00 >1.94E+03 Y Y
HDLSX-159 7.94E-04 3.96E-01 4.99E+02 Y Y
HDLSX-127 9.26E-04 >1.33E+00 >1.44E+03 Y Y
HDLSX-21 2.72E-03 1.34E-01 4.92E+01 Y Y
HDLSX-208 2.77E-03 >1.33E+00 >4.80E+02 Y N
HDLSX-79 3.26E-03 1.83E+00 5.61E+02 Y Y
HDLSX-27 3.36E-03 9.97E-03 2.97E+00 N N
HDLSX-177 3.56E-03 >1.33E+00 >3.73E+02 Y N
HDLSX-84 4.84E-03 1.07E-01 2.21E+01 N N
HDLSX-23 5.09E-03 2.29E-01 4.50E+01 N N
HDLSX-179 5.94E-03 1.37E-01 2.31E+01 N N
HDLSX-130 6.75E-03 >1.33E+00 >1.97E+02 Y N
HDLSX-209 6.86E-03 4.40E-02 6.41E+00 N N
HDLSX-18 7.15E-03 >1.33E+00 >1.86E+02 Y Y
HDLSX-22 7.42E-03 >1.33E+00 >1.79E+02 Y Y
HDLSX-39 7.55E-03 6.92E-02 9.17E+00 N N
HDLSX-213 9.05E-03 >1.33E+00 >1.47E+02 Y N
HDLSX-13 9.24E-03 >1.33E+00 >1.44E+02 Y N
HDLSX-72 9.53E-03 1.69E-01 1.77E+01 N N
HDLSX-126 1.02E-02 >1.33E+00 >1.30E+02 Y N
HDLSX-114 1.03E-02 5.92E-03 5.73E-01 N N
HDLSX-37 1.18E-02 9.93E-02 8.42E+00 N N
HDLSX-180 1.47E-02 >1.33E+00 >9.06E+01 Y N
HDLSX-9 1.47E-02 >1.33E+00 >9.03E+01 Y Y
HDLSX-8 1.48E-02 7.26E-02 4.92E+00 N N
HDLSX-40 1.61E-02 9.71E-02 6.05E+00 N N
HDLSX-44 1.74E-02 >1.33E+00 >7.63E+01 Y N
HDLSX-28 1.78E-02 1.32E-01 7.45E+00 N N
HDLSX-85 1.89E-02 >1.33E+00 >7.04E+01 Y N
HDLSX-211 1.90E-02 >1.33E+00 >7.00E+01 Y N
HDLSX-145 2.06E-02 7.91E-01 3.85E+01 N N
Table 3.1: The 38 potent hits (EC50 < 0.025 mg/ml against axenic amastigote L. mexicana)
were counter screened against mammalian vero cells. Those with a selectivity index (SI) >48 were
initially selected. Final selection (12 hits, Y= Yes, N = No) was made after subtracting those with
known cytotoxicity and intellectual property issues, and de-replication.
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3.3 Primary Fractionation and Secondary Screen-
ing
The 12 hit compounds then underwent fractionation, yielding 24 fractions per sam-
ple. 10 of theses compounds had components demonstrating activity against axenic
amastigotes at 1 mg/ml (HDLEX-9, 18, 79, 21, 22, 159, 171, 35, 67, 127; Figure
3.1). Initial mass spectrometry analysis (Figure 3.2) indicated the complexity and,
in some cases, content of the active fractions. For example, striatals (including
striatal B (Sub-figure 3.2) were present in HDLEX-21 (from 2007.20 HFN65 Cy-
athus cf. crassimurus). This group of compounds has previously been shown to
have antileishmanial activity [96]. A pure sample of the related compound striatal
B (XR562) was tested and found to have an EC50 of < 0.8 µM, but was toxic to
mammalian cells. Other compounds identified at this stage and deprioritised were a
glycolipid from HDLSX-18 (HFN67, Dacryopinax sp.), which had low potency with
an EC50 > 100 µM and the known metabolite nitidon from HDLSX-67 (HFN528
Junghuhnia nitida), which is cytotoxic against other cell lines [97].
3.4 Secondary Fractionation
Secondary fractionation was carried out on the 8 remaining active compounds (HDLEX-
9, 21, 22, 159, 171, 35, 127) of the primary screen as they demonstrated chemi-
cal novelty (Figure 3.3). Fractions were screened against axenic amastigotes at 1
mg/mL. HDLSX-9, 22, and 127 derived fractions had components demonstrating
activity against axenic amastigotes, although further fractionation of the 5 other
primary fractions (including from HDLSX-21 not containing striatal B) did not
yield samples with high level activity. Initial analyses by mass spectrometry indi-
cated the complexity and, in some cases, content of the active fractions. Informed
by these analyses, secondary fractions were screened against axenic amastigotes if
pure (HDLSX9Fr9+10F7 and HDLSX127Fr11Fr9; Figure 3.3 A and G) or further
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A
B
Figure 3.2: Spectrum of compounds. A peak (6.5 min) in fraction 14 of HDLSX-21 had a product
MH+ m/z 489.6, MNH4+ m/z 506.6 in the positive ion spectrum green peaks) and [M-H]- m/z
487.6 in the negative ion spectrum (purple peak). This corresponds to known antimicrobial striatal
B.
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fractionated (from HDLSX-22; Figure 3.3 D) before screening. The pure HDLSX-9
(HDLSX9Fr9+10F7) secondary fraction had minimal activity against the L. mexi-
cana amastigotes with an EC50 > 100 mM.
3.5 Tertiary Screening
For the tertiary screen, fractions (11-24 fractions) and other extracts provided by
Hypha shown in Table 3.2 were then screened at 1 mg/mL in a M379 L. mexicana
in a high throughput AlamarBlue® single point assay.
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Name Active/Not Active Name Active/Not Active
HDSLX-35 (Fr 14) Fr 1-10 Not active HDSLX-35 (Fr 15) Fr 1-3 Not active
HDSLX-35 (Fr 14) Fr 11 Not active HDSLX-35 (Fr 15) Fr 4 Not active
HDSLX-35 (Fr 14) Fr 12-19 Not active HDSLX-35 (Fr 15) Fr 5-7 Not active
HDSLX-35 (Fr 14) Fr 20-21 Not active HDSLX-35 (Fr 15) Fr 8 Not active
HDSLX-35 (Fr 14) Fr 22 Not active HDSLX-35 (Fr 15) Fr 9-11 Not active
HDSLX-35 (Fr 14) Fr 23-24 Not active HDSLX-35 (Fr 15) Fr 12 Not active
HDSLX-35 (Fr 14) Fr 25 Not active HDSLX-35 (Fr 15) Fr 13-16 Not active
HDSLX-35 (Fr 14) Fr 26 Not active HDSLX-35 (Fr 15) Fr 17 Not active
HDSLX-35 (Fr 14) Fr 27-28 Not active HDSLX-35 (Fr 15) Fr 18-19 Not active
HDSLX-35 (Fr 14) Fr 29 Not active HDSLX-35 (Fr 15) Fr 20 Not active
HDSLX-35 (Fr 14) Fr 30-31 Not active HDSLX-35 (Fr 15) Fr 21 Not active
HDSLX-35 (Fr 14) Fr 32-33 Not active HDSLX-35 (Fr 15) Fr 22 Not active
HDSLX-35 (Fr 14) Fr 34-48 Not active HDSLX-35 (Fr 15) Fr 23 Not active
HD871-1 Active HDSLX-35 (Fr 15) Fr 24-48 Not active
HD871-2 Active 2007.117.3 EtOAc EXTRACT Not active
HDSLX-171 (2007.117.3) Fr 7 Not active HDSLX-171 (2007.117.3) Fr 21 Not active
HDSLX-171 (2007.117.3) Fr 8 Not active HDSLX-171 (2007.117.3) Fr 22 Not active
HDSLX-171 (2007.117.3) Fr 9 Not active HDSLX-171 (2007.117.3) Fr 23 Not active
HDSLX-171 (2007.117.3) Fr 10 Not active HDSLX-171 (2007.117.3) Fr 24 Not active
HDSLX-171 (2007.117.3) Fr 11 Not active HDSLX-171 (2007.117.3) Fr 25 Not active
HDSLX-171 (2007.117.3) Fr 12 Not active HDSLX-171 (2007.117.3) Fr 26 Not active
HDSLX-171 (2007.117.3) Fr 13 Not active HDSLX-171 (2007.117.3) Fr 27 Not active
HDSLX-171 (2007.117.3) Fr 14 Not active HDSLX-171 (2007.117.3) Fr 28 Active
HDSLX-171 (2007.117.3) Fr 15 Not active HDSLX-171 (2007.117.3) Fr 29 Not active
HDSLX-171 (2007.117.3) Fr 16 Not active HDSLX-171 (2007.117.3) Fr 30 Not active
HDSLX-171 (2007.117.3) Fr 17 Not active HDSLX-171 (2007.117.3) Fr 31 Not active
HDSLX-171 (2007.117.3) Fr 18 Not active HDSLX-171 (2007.117.3) Fr 32 Not active
HDSLX-171 (2007.117.3) Fr 19 Not active HDSLX-171 (2007.117.3) Fr 33 Not active
HDSLX-171 (2007.117.3) Fr 20 Not active HDSLX-171 (2007.117.3) Fr 34 Not active
2007.117.3 BM EXTRACT Active XR562 Active
Table 3.2: Fractions and some other extracts provided by Hypha were screened at 1 mg/mL in
M379 L. mexicana.
From this first tertiary screen, pure HDLSX-127 secondary fraction (HD871-1;
HDLSX-127Fr11Fr9 in Figure 3.3) and three other compounds (2007.117.3 BM EX-
TRACT, XR562 and HD871-2 ) were used in various assays. Utilising a previously
established assay [54,71], compounds were tested against infected macrophages and
for macrophage cytotoxicity, as shown in Figure 3.4 and Table 3.3. For the axenic
L. mexicana amastigote dose-response assay, Amphotericin B and DMSO controls
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gave expected results in each instance. Compounds HD871-1, HD871-2, XR562,
and 2007.117.3 BM EXTRACT all gave EC50 value of 10 mM. Likewise for the
macrophage assays Cyclohexamide and DMSO controls also gave expected results
and these four compounds gave high EC50 values of HD871-1 at 23.80 mM, HD871-2
at 16.49 mM, and 2007.117.3 BM EXTRACT at 250 mM showing non-toxic effects
against the macrophages, these were then used in the L. mexicana intramacrophage
assays. XR562 at 0.84 mM showed toxicity towards the macrophages. The three se-
lected compounds having passed the toxicity assay were then used in the L. mexicana
intramacrophage assay . This ex vivo assay is known to mimic in vivo amastigotes
during clinical forms of cutaneous leishmaniasis, was used [95]. For L. mexicana
intramacrophage assay, both controls were within expected ranges and four com-
pounds tested gave respectable EC50 values (HD871-1 at 4.32 mM, HD871-2 at 5.32
mM, XR562 at 2.14 mM and 2007.117.3 BM EXTRACT at 700 mM). The two com-
pounds demonstrating a promising profile with respect to efficacy HD871-1 at 4.32
mM, HD871-2 at 5.32 mM with a selectivity of 5.51 and 6.23 respectively were then
used in metabolic studies.
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Figure 3.4: Dose-response curves for four compounds tested in the macrophage cytoxicity assay
indicate that HD871-1, and HD871-2 gave high EC50values (blue line.) Dose-response curves for
HD871-1, HD871-2 and XR562 compounds tested in the L. mexicana intramacrophage assays in
black plot line gave low EC50, while all four compounds tested in the L. mexicana axenic assays
in green line gave an EC50value of > 10 mM.
Compounds Axenic
(black
plot line)
95%CI SD Cytoxicity
(blue
line)
95%CI SD Infection
(green
line)
95%CI SD
HD871-1 3.39 mM 1.32 4.35 23.80 mM 2.531 5.63 4.32 mM 2.39 4.42
HD871-2 5.81mM 2.81 5.33 16.49 mM 2.13 4.23 5.32 mM 2.72 3.92
XR562 0.20 mM 2.17 5.68 0.84 mM 2.51 4.28 2.14 mM 3.33 4.37
2007.117.3 BM EXTRACT 0.5 mM 1.72 6.15 200 mM 1.53 3.98 700 mM 3.0 4.33
Table 3.3: EC50 of compounds tested in axenic, macrophages (toxicity) and intramacrophage
(infection) assays, that correspond to Figure 3.4
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The 313 compounds in the primary and secondary screens were tested and 64
selected compounds into a third single point assay screen, from which 10 showed
an inhibition of greater than 80%. The level of activity of 6 of the compounds that
showed <50% inhibition in the dose-response axenic assay, and were not effective
enough to pass through to the next round of anti-leishmanial screening. Therefore, 4
compounds with EC50values of under 10 mM went through to macrophage and intra-
macrophage assay testing. A concentration range of 100 mM was used in Figure 3.4.
HD871-1, HD871-2, XR562, and 2007.117.3 BM EXTRACT displayed the lowest
EC50 in the axenic assay, while also maintaining a low EC50 in the intramacrophage
assay but high EC50 in the toxicity macrophage assay (Figure 3.4).
The results were promising, and while 60 of the compounds did not meet the
experimental threshold, 4 of the compounds were efficacious against L. mexicana
amastigotes. The macrophage assay eliminated XR562 from the hit list as it gave a
low EC50 of 0.84 mM and is therefore toxic to mammalian cells, while HD871-1 and
HD871-2, and 2007.117.3 BM EXTRACT gave an EC50value < 10 mM in the same
assay. HD871-1 and HD871-2 yielded excellent results giving an EC50of 3.39 mM and
5.81 mM in the axenic assay respectively, and high EC50values of 23.80 mM (HD871-
1) and 16.49 mM (HD871-2) for the toxicity assay, while maintaining low EC50 in
the intramacrophage assays. The inhibition against L. mexicana shown by these
two compounds when compared to the EC50(> 10 mM) of the current frontline and
second-line anti-leishmanial drugs, like miltefosine and amphotericin B, warranted
further exploration. The two hit compounds one of which is shown (Figure 3.5) were
therefore used in metabolomic analysis in the search for their targets.
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Figure 3.5: Molecular structure of HD871-1
3.6 Anti-leishmanial conclusions
This chapter, describes the screening of 313 extracts from the Hypha Discovery com-
pound library against L. mexicana. Four compounds with anti-leishmanial proper-
ties (EC50 of less than 10 mM) in the axenic and L. mexicana intramacrophage assays
were identified although only two of the compounds showed low mammalian cyto-
toxicity. These two hit compounds, HD871-1 and HD871-2, were selected for further
analyses.
Chapter 4
Results: Metabolomic analyses
In this chapter we examine the two hit compounds HD871-1 and HD871-2 identified
from the assays in chapter 3. The aim was to explore effects on metabolism of
compounds HD871-1 and HD871-2 in L. mexicana axenic amastigotes.
4.1 Preliminary work on metabolomics in Leishma-
nia
Previous studies examined the metabolic effects of miltefosine, the first approved
oral drug for the treatment of leishmaniasis [88]. These studies showed that af-
ter exposure to miltefosine the known metabolites including sterols and other lipid
pathways are affected within Leishmania species.
4.1.1 Half-time to death assay
A half time to death assay was carried out to identify the optimum concentration
to be used in examining the effect of HD871-1 and HD871-2 on the L. mexicana
amastigote metabolome. The optimum conditions for cell extraction of L. mexicana
amastigotes metabolome as determined by the half time to cell death assay for
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HD871-1 and HD871-2 exposure, was determined as 10 mMwith a 36 hour compound
exposure, as disscused below.
4.2 Metabolomic determination of Leishmania re-
sponse to HD871-1 and HD871-2
Analyses were carried out on treated and untreated L. mexicana axenic amastigotes
using DMSO as a control. The effect on metabolites associated with samples treated
with HD871-1 or HD871-2 and without compound was then determined. Approx-
imately 500 were detectable and a selected few shown in Table 4.1. Identification
of metabolites took place when the metabolome in question increased or decreased
following exposure of either HD871-1 and HD871-2 in a 36 hour time period. Sig-
nificant changes were evaluated as these with a P value of < 0.05 and a fold change
of ± 3-4 for at least one of the comparisons made.
4.3 Effect on nucleotide metabolism post-exposure
to HD871-1 and HD871-2
Treated samples experienced an increase in deoxynucleotide monophosphates and a
decrease in deoxynucleotide diphosphates (Figure 4.1). These changes point to alter-
ations in DNA metabolism, but the impact on cell viability is not certain. Profound
decreases in orotate and dihydroorotate also point to an alteration of pyrimidine
biosynthesis, but pyrimidines themselves were not diminished, presumably due to
the parasite’s ability to transport and interconvert pyrimidines [98].
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4.4 Effect on trypanothione metabolism post-exposure
to HD871-1 and HD871-2
Trypanothione, the bis(glutathionyl) spermidine adduct that performs key redox
roles in Leishmania spp and other trypanosomatids, was greatly diminished in
treated cells. The peak of this compound (Table 4.1) (m/z = 361.6527 corresponding
to the doubly positively charged trypanothione) was poorly resolved by chromatog-
raphy, hence quantitative comparison is not possible, but treated cells contained
profoundly less signal for this mass than untreated cells (Figure 4.2) In addition to
reduced trypanothione, its oxidised disulphide derivative, (m/z = 361.6441), was
also 3-4 fold less abundant in treated cells, and its thiol precursor glutathione (m/z
= 307.0837) also diminished in abundance by >60% in the treated cells. Another
poorly resolved peak consistent with oxidised cysteine derivative, cystine (m/z =
240.0238) was identified in treated, but not untreated cells. In summary; NADPH,
trypanothione, trypanothione disulfide, spermine, glutathione, L-cysteine and S-
glutathionyl-L-cysteine all linked to the trypanothione pathway, were identified in
the metabolic analyses of L. mexicana.
4.5 Possible modes of action HD871-1 and HD871-2
As observed, in both the L. mexicana HD871-1 and HD871-2 treated parasites,
the metabolome affected, either by an increase or decrease, pointed towards the
trypanothione and nucleotide metabolism pathways. Trypanothione in kinteoplatids
has been well studied [99] and a complex formed between spermidine and glutathione
is used in the maintenance of thiol–redox balance during defence against reactive
oxygen species. This thiol redox system is essential for all trypanosomatids living
in the human host, and it is the importance of thiol–redox metabolism that has
been exploited, by identifying key enzymes involved in this pathway, leading to the
development of anti-kinetoplastidal compounds [99].
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For the untreated L. mexicana, the metabolism of trypanothione (Figure 4.3)
in this parasite can be divided into three parts; synthesis, regeneration and utiliza-
tion [99]. During synthesis, trypanothione synthatase (TS) ligates two glutathione
molecules to a single molecule of spermidine (or spermine) using ATP as an energy
cofactor, this trypanothione compound is then used in various processes of detoxifi-
cation ( for example xenobiotics), cell proliferation, protein thiol-redox homeostasis
and protection against oxidants. The regeneration process involves trypanothione
reductase (TR) and the recycling of NADPH and NADP to produce more try-
panothione, this trypanothione also interchanges to trypanothione disulphide using
tryparedoxin.
Figure 4.3: Untreated L. mexicana trypanothione metabolism, involving trypanothione synthase
catalysing 2 gluthatione + 1 spermidine + 2 ATP molecules during synthesis to generate one
trypanothione molecule and regenerating trypanothione through trypanothione reductase using
NADPH, which can be supplied by the oxidative phase of the pentose phosphate pathway via
glucose 6-phosphate dehydrogenase [99].
However, in the HD871-1 and HD871-2 treated samples the key metabolites,
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starting with trypanothione were reduced relative to the untreated samples Figure
4.4, this was also a likely result of there being a lower amount of glutathione during
the synthesis process. The regeneration process which involved the use of NADPH,
was also lower in these treated parasites, which may also have lead to the reduced
amount of trypanothione disulfide. As expected, and seen in most pathways, the
decrease in one area of metabolism, can increase of metabolism in another. Hence,
the decrease in the trypanothione metabolome pathway resulted in an increase in
upstream metabolomes. Activation of cysteine metabolism pathway, fits in with the
increased amount of glutathione available, causing increased amounts of L-cysteine,
cysteine and S-Glutathionyl-L-cysteine. The reduced amount of trypanothione of the
treated L. mexicana could have been a result in the compounds inhibiting enzymes
involved in this pathway, leading to an imbalance of the thiol-redox system, and
increase in reactive oxygen species, and reduced cell proliferation.
Figure 4.4: HD871-1 and HD871-2 treated L. mexicana trypanothione metabolism shows a lack of
activity in trypanothione synthase catalysis in the combination of 2 glutathione + 1 spermidine
+ 2 ATP molecules during synthesis and lack of regeneration of trypanothione disulfide through
trypanothione reductase using NADPH. This may have lead to oxidative stress and resulted in
parasite death.
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4.6 Putative drug targets
The comparison between treated and untreated samples highlighted the likely im-
portance that trypanothione and nucleotides play in terms of parasite survival. With
respect to nucleotide metabolism changes in the deoxynucleotide pool indicated pos-
sible changes in DNA metabolism, although whether this is a cause of cell death is
unclear and secondary effect due to other changes is not clear and make it difficult
to identify a target. For trypanothione metabolism however, trypanothione reduc-
tase and trypanothione synthase may well be the target of the two hit compounds,
as the levels of trypanothione were reduced. The lack of trypanothione disulfide
and NADPH also pointed towards inhibition of trypanothione reductase. Further
investigation into which enzyme is affected by the compound would be the next step
to define the precise target.
4.7 Metabolomic analysis conclusions
The experiments described in this chapter, illustrate the use of a robust platform
offering broad coverage of Leishmania metabolites in addition to identifying the
effects on the trypanothione pathway as a result of the treatment of HD871-1 and
HD871-2. Many other pathways were also shown to be perturbed by theses two
compounds. HD871-1 and/or HD871-2 which may inhibit trypanothione biosnthesis
(synthase/reductase) in L. mexicana coupled to the non-toxic effects shown in the
macrophage assays. The low EC50 values from the intramacrophage drug screens
shown in the previous chapter make these natural compounds ideal candidates for
drug target validation and further in vivo studies.
Chapter 5
Results: An investigation into
natural compounds and Pex
inhibitors for Toxoplasma gondii
In this chapter we explore the use of another natural compound Aureobasidin A
(AbA), and its derivatives against T. gondii Type I and Type II. From previously
published work, Wuts et al 2015. showed that the activity of Aureobasidin A-
derivatives on fungal pathogens gave similiar efficacy values (typically < 0.5 mM) [13].
These compounds have also previously been shown to be active against yeast and
asks the question of whether they, would be active against protozoa. Here we report
the EC50 of AbA and its derivatives against T. gondii Type I and Type II, showing
that one of the AbA derivative is active against Type II T. gondii the encysted form
of Toxoplasma, and could potentially be used in treatment of chronic toxoplasmosis
when the parasite is in the bradyzoite form.
The research contained in this chapter has been previously published in a peer
reviewed paper:
• Alqaisi, A Q I and Mbekeani, A J and Llorens, M Bassas and Elhammer,
A P and Denny, P W, "The antifungal Aureobasidin A and an analogue are
active against the protozoan parasite Toxoplasma gondii but do not inhibit
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sphingolipid biosynthesis", Parasitology 145 (2018), pp. 148--155.
5.1 Preliminary work on Aureobasidin A
AbA is a well known depsipeptide produced by Aureobasidium pullulans strain BP-
1938 and targets the fungal inositol phosphorylceramide (IPC) synthase, an enzyme
in the sphingolipid biosynthesis pathway. In addition, AbA has been shown to be
active against various species of Leishmania and other protozoa [82,100].Wuts et al
2015, synthesised a library of approximately 30 compounds based on the parent AbA
structure and Dr Ake P. Elhammer at AureoGen Biosciences carried out testing on
Candida albicans. From these results we selected the four compounds shown in
Figure 5.1 [13] that showed the highest potency against C. albicans and Aspergillus
fumigatus for testing against Toxoplasma.
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(a) Aureobasidin A (AbA)
(b) Compound 20 (AbA-3-pyridyl)
(c) Compound 26F (AbA-fluorophenyl)
(d) Compound 3 (AbA + Br)
(e) Compound 4 (ABA+I)
Figure 5.1: Aureobasidin A and derivatives synthesised by Wuts et al 2015.
5.2. EC50 of Aureobasidin A and derivatives against Type I Toxoplasma
gondii 90
Compounds C. albicans EC50[mg/mL]
Compound 3 0.03
Compound 4 2.50
Compound 20 0.05
Compound 26F 0.05
Table 5.1: C. albicans data showing that compound 26F has the lowest EC50 [13]
5.2 EC50 of Aureobasidin A and derivatives against
Type I Toxoplasma gondii
In order to test the activity of these natural compounds against Type I Toxoplasma
gondii, four AbA derivatives and AbA were screened against YFP tagged RH Tox-
oplasma tachyzoites [101]. The methodology, is described in detail in Chapter 2,
breifly, HFF cells were infected with Type I parasites and after 20 hours, compounds
were added and fluorescence analyzed using a macro-data spreadsheet (Appendix
A) The data output was used to generate an EC50 and produce a sigmoidal dose-
response curve in Prism V7. Results were plotted using percentage growth versus
log concentration (Figure 5.2). Positive (AbA) and negative controls gave expected
results on each occasion.
As shown in Table 5.2, all four compounds showed activity against Type I T.
gondii and gave varied EC50 values, with the lowest coming from AbA. Since com-
pound 20 was the more potent at 48 hrs 0.75 mg/mL than compound 3 0.89 mg/mL
, it was decided that this compound would be suitable for testing against encysted
form of T. gondii.
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Figure 5.2: EEfficacy of Aureobasidin A, Compound 3, 4, 20 and 26F against Toxoplasma Type
I. Compound 3 and Compound 20 gave the highest activities at 48 hours, similar to Aureobasidin
A.
5.3. Testing Aureobasidin A and derivatives against Type II
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Compound EC50[mg/mL] 95%CI SD
AbA 0.44 1.25 4.40
Compound 3 0.89 2.52 4.73
Compound 4 1.34 1.63 5.24
Compound 20 0.75 1.34 4.53
Compound 26F 10.79 1.20 1.86
Table 5.2: Efficacy of Aureobasidin A, Compound 3, 4, 20 and 26F against Toxoplasma Type I.
5.3 Testing Aureobasidin A and derivatives against
Type II Toxoplasma gondii
As AbA and Compound 20 were the most potent in the 48 hour drug screen against
Type I T. gondii, both were selected for testing against the GFP-tagged Toxoplasma
Type II Pru strain [92]. As described in Chapter 2, breifly, HFF cells grown on
96 well plates were infected with the Type II parasites before transformation to
bradyzoites. Encysted bradyzoites were then treated with compounds and incubated
for 3 days after which fluorescence was measured and analyzed using a macro-data
spreadsheet (Appendix B). The data output was used to calculate an EC50 in Prism
V7 and results were plotted as inhibition versus log concentration. Both AbA and
Compound 20 (Figure 5.3) showed activity against encysted Type II Toxoplasma
gondii and gave EC50values of 2.51 mg/mL and 3.74 mg/mL respectively. These two
compounds proved to be potent inhibitors of encysted Type II Toxoplasma gondii
showing low mammalian cytotoxicity. In addition to promising pharmacokinetic
properties of Compound 20 [13], this class of cyclic depsipeptides could be used in
future experimentation, in vivo and potentially on clinical trials, to treat chronic
toxoplasmosis and some psychiatric disorders. [82] .
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Figure 5.3: EC50of Aureobasidin A and Compound 20 against T.gondii Type II
5.4 Screening Pex5-Pex14 inhibitors against intra-
cellular RH Toxoplasma gondii
The Pex5-Pex14 interaction is crucial for lipid transport in protozoa [41,102]. Com-
pounds 5MA, CMPD 11 NH2, 5MA NH2, 6MA, DOL 320, MAB NH2, PR DD 43,
PR DD 51 provided by Prof. Ralf Ederman at Ruhr University, Germany are Pex5-
Pex14 inhibitors that disrupt glycosomal protein import and killing trypanosomes
by affecting the Pex5-interaction site specifically in T. brucei. In addition, these
compounds are active against Pex14 in other protozoa such as T. cruzi and Leish-
mania Pex14 [102]. To investigate this class of compounds further, we utilized the
availability of these eighteen Pex5-Pex14 inhibitors to test their efficacy against
Toxoplasma.
For these experiments, T. gondii tachyzoites RH Type I with YFP [101] were
inoculated into HFF cells and compounds added after 18 hrs at concentrations from
0.21mM to 50 mM; pyrimethamine was used as a positive control and DMSO the
negative control. Florescence was mesasured in plates and data analysed as before.
Eleven hit compounds were identified in this screen. All with an EC50 of < 10 mM
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Table 5.3. Interestingly, all of the hit compounds exhibited host toxicity at higher
concentrations 16.67 mM and/or 50 mM. The assay was robust and gave a Z factor
of > 0.80.
Compounds EC50 95%CI
5M 33.77 15.56 - 73.32
5MA 6.83 5.35 - 8.71
5M III 21.68 very wide
5 III MAB N/A N/A
DOL 008 13.80 very wide
DOL 145 110.40 very wide
CMPD 11 46.43 very wide
CMPD 11 NH2 0.96 0.80 - 1.14
5MA NH2 6.57 1.94 -22.23
6MA 4.33 4.15 - 4.52
DOL 320 6.96 4.09 - 11.82
DOL40-4 49.21 very wide
MABAM POL 6.13 very wide
MAB NH2 1.16 1.50 - 1.75
PR DD 43 4.00 3.28 - 4.88
PR DD 51 6.64 3.53 - 12.47
5G 48.09 very wide
Table 5.3: T. gondii Pex5-Pex14 EC50 assay with 17 test compounds. Very wide (< 60)
5.5 Toxoplasma compound screen conclusion
In conclusion the work described in this chapter involved the screening of 4 Au-
reobasidin A-derivatives in T. gondii and C. albicans drug assays. Compound 3
and Compound 20 showed the highest activity in the C. albicans assays. In the T.
gondii assays compound 20 showed highest potency in both tachyzoite and brady-
zoite forms. Additional testing of 18 compounds that target peroxins showed that
eleven compounds had a low EC50 against T. gondii but also displayed high mam-
malian cytoxicity. Further exploration of their potential as Pex5 or Pex14 inhibitors
was not warranted due to their toxicity against mammalian cells. Optimisation of
these compounds to reduce their toxicity to mammalian cells could potentially be
pursued and lead to the development of a non-toxic Pex protein inhibitor as achieved
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with other protozoan research [1, 2, 7]. However, in order to discover target specific
inhibitors, there needs to be a closer examination and analysis of the Pex5 protein
at a bioinformatic level that could help in determining a mode of action. Addition-
ally, identifying key regions in the peroxins that are unique to the parasite could
lead to subsequent medicinal chemistry optimisation of the eleven potent inhibitors
identified here. Binding sites such as the TPR domains found in Pex5 described in
the next chapter, could be exploited in the discovery of a specific Pex5 inhibitor.
Chapter 6
Results: Evaluation of peroxisomal
proteins TgSCP2 and TgPex5
Having identified eleven inhibitors of Pex5 and Pex14 in Toxoplasma, attention
turned to reviewing the biological properties of Pex proteins, in particular Pex5 and
its associated protein ligands SCP2. To begin the functional analysis of TgPex5,
and TgSCP2 a sequence comparison of Pex5 proteins from S. cerevisiae, T. gondii
and H. sapiens, was compiled. Expression data on peroxisomal proteins was also
undertaken. In addition, the results of functional complementation studies between
yeast Toxoplasma and humans was also reported. The possible location of perox-
isomes within the tachyzoite forms of Toxoplasma was also explored, as was the
interaction between the peroxisomal proteins TgSCP2PTS1 and TgPex5C-TERMINAL.
The research contained in this chapter has been previously published in a peer
reviewed paper:
Alison J. Mbekeani, W Stanley, V Kalel, N Dahan, E Zalckvar, L Sheiner. “Func-
tional Analyses of a Putative, Membrane-Bound, Peroxisomal Protein Import Mech-
anism from the Apicomplexan Protozoan Toxoplasma gondii”, Genes 9, 9 (2018), pp.
434.
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6.1 Exploring Pex5
6.1.1 Gene Expression of TgPex5 and TgSCP2
A clear difference in the amount of TgSCP2 expressed at different stages of the
parasites life-cycle is evident, showing highest levels in the oocyst stage (Figure
6.1). One explanation for this is that the increase in expression of TgSCP2 is linked
to the parasites requirement for sterol just prior to the entry into the dormant,
sporulated oocyst stage. This could involve, the addition of further lipid bilayers
within membranes increasing the transport of lipids into the peroxisome just before
oocyst formation.
Figure 6.1: Expression level of TgSCP2 at different stages in T.gondii life-cycle. Data obtained
from toxodb.org [103]
As would be expected, TgPex5 expression parallels the expression pattern of TgSCP2
and as shown in Figure 6.2. As with TgSCP2, TgPex5 is highly expressed in the
oocyst stages and moderately expressed in the bradyzoite and tachyzoite stages.
The higher expression of TgPex5 in the oocyst, like TgSCP2, could be attributed to
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preparation for the next stage of the parasites life-cycle, where a sporulated oocysts
may potentially require the function of the peroxisome.
Figure 6.2: Expression level of TgPex5 at different stages in T.gondii life-cycle. Data taken from
toxodb.org [103]
6.1.2 Sequence alignments of Pex5
The Pex5 receptor is conserved in many species (Figure 6.3) is mainly characterised
by two domains: the N-terminal domain, which has copies of a unique pentapeptide
motif, WXXX(F/Y) and the C-terminus which contains tetratricopeptide repeats
(TPR) [40,42,43,45,80,104]. The number of N-terminal pentapeptide motifs varies,
where S. cerevisiae Pex5 has two, Leishmania donovani and Trypanosoma brucei
have three and Homo sapiens have seven. These seven pentapeptide motifts has
been shown to bind to Pex14 in mammal [41]. In contrast, the C-terminal TPR
region of Pex5 has seven degenerate 34 amino acid motifs present in all species and
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is involved in PTS1 binding [105] . Deletion of the TPR domain at the Pex5 C-
terminus is not sufficient to disrupt functionality, indicating a distinct functionality
for the N-terminal region of Pex5 [106].
Figure 6.3: Schematic representation of the Pex5 protein from 5 different species, including
TgPex5. All show characteristic TPR domains (orange) at the C-terminal end, pentapeptide
motift (blue) and the Pex7 binding domain (red). In Toxoplasma, The Pex7 recognition domain
is not known. Adapted from [104].
The N-terminal domain of Pex5 is known to bind to Pex7 [41, 104]. This Pex5
receptor, mainly cytosolic, is believed to have six WD domains in most species as
depicted in Figure 6.3 . The WD domains are approximately 50 amino acids long
and end with a tryptophan-aspartic acid pair. These WD repeats were reported to
fold into anti-parallel b-sheets and the structure of human Pex7 has been shown to
have a PTS2 binding site as well as binding sites for chaperones [41,104]. Pex7 in L.
major, T. brucei and H. sapiens use Pex5 as a chaperone while S. cerevisiae Pex7
relies on other peroxins such as Pex13 and Pex14 [41]. TgPex7 could be similar
to either yeast or L. major, T. brucei and H. sapiens. [40]. Figure 6.4 provides
a comparision of the N-terminal and C-terminal domains, highlighting the regions
to which PTS1 and Pex7 bind, but also key residues required for Fox1 interaction,
which appear to be conserved. The Fox1 binding regions reside in the N-terminal
half of ScPex5 asequence homology here is consitant with TgPex5 having a similar
site [80, 107].
6.2. Exploring the function of TgPex5 in yeast 100
Figure 6.4: Toxoplasma Toxoplasma Peroxin 5 (Pex5) contains structures with yeast and human
Pex5. Comparison of Toxoplasma Pex5 protein with yeast and human counterparts indicated the
presence of critical cysteine and lysine residues (C, K), pentapeptide motifs (WxxxF/FxxxW)
and structural domains (Pex7-binding region and TPRdomains which bind peroxisomal-targeting
signal 1 [PTS1] ligands). Additionally, a region homologous to the Fox1 binding site in yeast Pex5
is also found in Toxoplasma Pex5 and is indicated by black arrowheads. (B) Sequence alignment of
the Fox1 binding site in yeast Pex5 (ScPex5251-267) with the predicted equivalent in Toxoplasma
Pex5 (TgPex5442-456), arrows indicate positions in ScPex5. [80]
Having seen the similarity between Pex5 proteins from S. cerevisiae, T.gondii
and H. sapiens further in vitro investigations were carried out to better understand
the function of T.gondii Pex5 and SCP2 proteins.
6.2 Exploring the function of TgPex5 in yeast
Investigating the function of TgPex5 in yeast cells involved both a qualitative and
quantitative approach. The qualitative analysis involved a spot test and an immuno-
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precipitation assay, while the quantitative analysis used optical density to monitor
growth.
6.2.1 Qualitative analysis
6.2.1.1 TgPex5 in yeast complementation spot test
Complementation of TgPex5 in yeast Pex mutants was tested after transformation of
pRS416-TgPex5 into WT (UTL7) and DPex5 yeast as detailed in methods Chapter
2. As can be seen in the spot test (Figure 6.5) - URA glucose and - URA oleate plates,
showed growth of both mutants and wild-type (empty vector) on the glucose plate.
On the oleate plate however, DPex5 empty vector yeast cells showed stunted growth
as there was a lack of glucose and inability to utilise oleate as an energy source.
This was represented by fewer yeast colonies and slower growth for the mutant and
is explained by the lack of the Pex5 within the yeast peroxisome. As can be seen,
this functionality of the peroxisome is restored when either ScPex5 and TgPex5 are
transfected back into the yeast mutants. Such that, in the yeast DPex5 + ScPex5
and DPex5 + TgPex5 growth was well established and represented by a halo around
the yeast colonies which is typical of oleate substrate utilisation (*). This spot
test indicated that TgPex5 did complement ,yeast DPex5 and clearly shows that
functionality of Pex5 in these mutants can be restored by either TgPex5 or ScPex5.
Additional analysis of these yeast colonies was carried out in an immunoflorecence
assay [80].
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Figure 6.5: TgPex5 yeast complementation spot test on -URA glucose and -URA oleate plates.
Mutants and wild-type (empty vector) show no growth difference on the glucose plates, while on
the oleate plate, only mutants with functional Pex5 showed robust growth, indicated by yeast
colonies surrounded by a halo (*).
6.2.1.2 TgPex5 yeast complementation immunoflorecence assay
Having identified that TgPex5 can restore functionality to DPex5 yeast cells in
a spot test, TgPex5 we visualised peroxisomes in mutant and transformed yeast
colonies. As in the spot test, the TgPex5 in yeast UTL7 Pex mutants was further
confirmed after pRS416-TgPex5 plasmids were transfected into wild-type UTL7 and
mutant DPex5 were grown in oleate and glucose substituted yeast media as detailed
in Chapter 2. After 24 hour incubation the IFA images in both glucose and oleate
were obtained Figure 6.6. In the negative control (top row) of both the glucose
and oleate media images as expected, the empty plasmid transfected into DPex5
yeast cells, did not show localisation as indicated by GFP signal throughout the
cytoplasm. However, agreement with the spot test results, puncta in the cytoplasm
indicate localisation of TgPex5 and ScPex5 to peroxisomes in the DPex5 yeast cells.
This spot test and immunoflorecence assay provide a good qualitative representa-
tion of TgPex5 restoring the functionality of mutant Pex5 yeast. In order to quantify
the functionality of TgPex5 in the yeast mutant, a growth assay was carried out.
The experiments with S. cerevisiae demonstrated that TgPex5 could clearly restore
GFP-PTS1 targeting to peroxisomes in a cellular context in the immunoflorecence
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assay. These results suggest that TgPex5, like ScPex5 restores peroxisomal function
and b-oxidation as characterised by increased growth and the utilisation of fatty acid
oleate, as indicated by the halo formation around the colonies on oleate plates [80].
6.2.2 Quantitative analysis
6.2.3 TgPex5 yeast complementation in oleate growth media.
Having clearly established the complementation of TgPex5 in yeast UTL7 Pex5 mu-
tants, transfected TgPex5-pRS416-WT wild-type UTL7 and mutant DPex5 were
grown in - URA oleate and - URA glucose media for 24 hrs as detailed in Chapter 2.
Growth of yeast cells was measured using optical density (OD) at 600 nM (Figure
6.7). As expected there was no significant difference in yeast cell growth between the
different strains in media containing glucose. However, when the food source was
substituted for oleate, there was a significant difference in growth between the nega-
tive control, the yeast mutant and wild-type strains over 24 hrs. The DPex5 mutant
expressing ScPex5 showed improved growth over the DPex5 mutant. Showing a 4
fold improvement in growth. The DPex5 mutant expressing TgPex5 also showed
improved growth 3 fold difference better than mutant one. These results, further
support the conclusion that TgPex5 is able to restore growth to a Pex5 mutant in
the absence of glucose, using oleate as an energy source.
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Figure 6.7: Complementation of yeast Pex5 mutant using TgPex5 during growth in oleate and
glucose media. Four replicates of each sample were performed . A t-test indicated a significant (P
< 0.05) difference between DPex5, and DPex5 carrying yeast Pex5 yeast and Toxoplasma Pex5.
Both the qualitative and quantitative analysis of the TgPex5 in yeast show that
TgPex5 can replace Pex5 function in yeast and indicating that peroxisome function-
ality has also been restored. Hence ScPex5 and TgPex5 seem to be functionally
interchangeable, playing a similar role in their respective organisms. The next stage
was to establish wether the same was true of human and Toxoplasma Pex5 proteins.
6.3 TgPex5 complementation in human fibroblasts
6.3.1 TgPex5 human fibroblast complementation immunoflo-
recence assay
After establishing sucessful complementation of TgPex5 in yeast, TgPex5 comple-
mentation in human Pex5 mutant fibroblasts was carried out, through the trans-
fection of pIRES2-EGFP-SKL-TgPex5 in wild-type fibroblast and DPex5 human
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fibroblasts as detailed in Chapter 2. After 72 hours the immunoflorecent images in
(Figure 6.8) indicate that, the empty vector in wild-type fibroblasts and the DPex5
fibroblasts carrying human Pex5 both show puncta within their cytoplasm’s. In
contrast, the empty vector in a Pex5 mutant fibroblast and the DPex5 fibroblasts
carrying Toxoplasma Pex5 did not show any puncta. The Pex5 mutant fibroblast
carrying the empty vector showed non-localised cytosolic GFP signal throughout
the cytoplasm. The lack of puncta strongly suggests that Toxoplasma Pex5 cannot
restore Pex5 functionality to DPex5 mutant human fibroblasts. This result supports
the bioinformatics analysis reported in the previous sections, in that the Toxoplasma
Pex5 gene does not carry all the some motifs present in the human Pex5 so it is not
too surprising that it was incapable of restoring functionality [80].
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Figure 6.8: TgPex5 human fibroblast complementation immunoflorecence assay shows that Tox-
oplasma Pex5 does not complement Pex5 in Pex5 mutant fibroblasts. Toxoplasma Pex5 and empty
vector both show GFP signal throughout the cytoplasm where as the positive control, human Pex5
with Pex5 mutant fibroblast do show localised peroxisomes. The scale bar is 10 µM.
In summary, these complementation studies indicate that the heterologous TgPex5
targets not only the artificial cargo GFP-PTS1, but also the endogenous yeast en-
zymes, into peroxisomes. Interestingly, this restored translocation of TgPex5 into
the organellar lumen of not only the b-oxidation enzymes with typical PTS1, but
also of the non-PTS acyl-CoA oxidase Fox1. Fox1 is the initial enzyme required for
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the fatty acid catabolic pathway. This also fits with the Fox1 binding regions have
being assigned to the N-terminal half of ScPex5 [107].
In conclusion, the functionality of mutant Pex5 yeast cells was restored when
Toxoplasma Pex5 was introduced, showing that it is a functional equivalent. Ad-
ditionally, the analysis also indicates that TgPex5 is cannot functionally replace
the human version of Pex5. Ideally we would show that Toxoplasma Pex5 localise
directly to the peroxisomes of Toxoplasma [80].
6.4 Localising peroxisomes in T .gondii
6.4.1 In vitro localisation of GFP-TgSCP2 in wild-type T.
gondii
After the transfection of parasites with TgSCP2-TUB8-myc-GFP-myo-ATy-HX (Chap-
ter 2) the transfected parasites were fixed and subsequently stained with DAPI, anti-
IMC inner membrane complex (IMC) and anti-GFP antibody. Figure 6.9 shows a
merged image of all three of these stains after 24 hours incubation. The nuclei of
both the parasite and HFF cells can be visualised using DAPI, as all four parasites
nuclei are stained blue. The IMC which is only present in the parasite, is stained
red in all four T. gondii. GFP-tagged TgSCP2 localises at the basal end of wild-
type T. gondii, suggesting that TgSCP2, with its PTS1 site, is co-localising with
TgPex5 or TgPex5 like molecule at basal end of the parasite. This localisation of
GFP-tagged TgSCP2 to the basal end of wild-type T. gondii is similar to that found
previously [24] Overexpression of GFP-tagged protein has been shown to localise at
the basal end of the parasite before, so in order to clarify this specificity we employed
GFP-ePTS1.
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Figure 6.9: GFP--tagged TgSCP2 localises at basal end of parasite when transiently expressed
in Toxoplasma. GFP-SCP2 is stained with anti-GFP antibody (green) and the parasite pellicle
stained with anti-IMC1 antibody (red) and nuclei stained with DAPI (blue). The scale bar is 1
µM.
6.4.2 In vitro localisation of GFP–ePTS1 in wild-type T.
gondii
In collaboration with Dr. Lilach Sheiner at Glasgow University.
In order to provide clearer quantitative analysis of the localisation of peroxisomes
within toxoplasma tachyzoites, enhanced (e)PTS1 was used. The GFP–ePTS1
which had been identified and used in yeast is a more efficient way of localising
PTS1 proteins when florencently tagged [75]. Therefore, when GFP-ePTS1 was ex-
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pressed in Toxoplasma, clear round bodies with diameters ranging from129-311 nm
were visible (Figure 6.10) This is similar to the sizes reported for peroxisomes with
a region of 100–200 nm and previous observations in this parasite [50] [52].
Figure 6.10: GFP tagged with ePTS1 localised to peroxisome-like bodies when transiently ex-
pressed in Toxoplasma. Two parasites within a HHF vacuole are seen with, GFP-ePTS1 stained
with anti-GFP antibody (A, green), the parasite pellicle stained with anti-IMC1 antibody (B, red),
and a merge of A and B (C). The scale bar is 1 µM.
This finial observation of punctate structures after localisation indicates that
PTS1 co-localises with Pex5 within Toxoplasma and supports the interactions be-
tween theses two proteins observed previously in S. cerevisiae. The determination of
a gennuine interaction between PTS1 and the C-terminal end of these Pex proteins
was further investigated by examining recombinant protein interactions in vitro
6.5 TgSCP2 and TgPex5 protein expression and
purification
6.5.1 Protein expression of HIS-GST-TEV-TgSCP2PTS1 and
HIS-GST-TEV-TgPex5c-terminal
Having identified peroxisome like structures in Toxoplasma, recombinant Pex pro-
teins were expressed and purified in order to establish an interaction between TgSCP2
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and TgPex5. Individual expression of the T.gondii fusion proteins , HIS-GST-TEV-
TgPex5c-terminal and HIS-GST-TEV-TgSCP2PTS1 was successful in E. coli BL21
cells.
6.5.2 HIS-GST-TEV-TgSCP2PTS1 protein purification
Expression of HIS-GST-TEV-TgSCP2PTS1 was followed by several purification steps.
The first stage of the purification was to pass the filtered sample containing pro-
tein from the soluble lysate through a GSTrap column. The eluted protein from
this column was visualised by SDS-PSGE as shown in Figure 6.11 (A) The band
at approximately 43.4 kDa representing HIS-GST-TEV-TgSCP2PTS1fusion protein
and overexpressed HIS6-GST at approximately 29 KDa. Following TEV protease
digestion in (B), three bands noted: un-cleaved HIS-GST-TEV-TgSCP2PTS1, HIS6-
GST and TgSCP2PTS1. After passingthis sample through the nickel affinity column
(NI-NTA) purified TgSCP2PTS1can be observed (C) at approximately 14.6 KDa. In
summary TgSCP2PTS1 protein was successfully overexpressed and purified.
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Figure 6.11: Purification steps of TgSCP2PTS1analysed by SDS-PAGE. 12.5% SDS-PAGE
gels of purified HIS-GST-TEV-TgSCP2PTS1 & TgSCP2PTS1 shown alongside a 100 kDa ladder.
Expected bands at 43.4 kDa (A) for fusion protein HIS-GST-TEV-TgSCP2PTS1, and after TEV
protease digestion in gel (B) TgSCP2PTS1(14.6 kDa)HIS-GST-tag (29 kDa) and undigested fusion
protein HIS-GST-TEV-TgSCP2PTS1. In (C) Sample after the Ni-NTA column, showing purified
TgSCP2PTS1(14.6 kDa).
6.5.3 HIS-GST-TEV-TgPex5c-terminal protein purification
As with HIS-GST-TEV-TgSCP2PTS1, the first stage in purification of the TgPEX5c-terminal
protein was to pass the cell lyste through a GSTrap column. Eluted protein form this
column contained the full-length fusion protein as shown in Figure 6.12 (A). The sin-
gle band at approximately 62.5 kDa represents the HIS-GST-TEV-TgPEX5c-terminalfusion.
TEV protease digestion produced, two bands. SDS-PAGE consisting of the cleaved
TgPex5c-terminal (35.4 kDa) and the HIS6-GST tag (29 kDa) Figure 6.12 (B). Nickel
affinity chromatography of this mixture yielded pure TgPex5c-terminal at approxi-
mately 34.5 kDa Figure 6.12 (C). Hence the TgPex5c-terminal protein was success-
fully expressed and purified.
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Figure 6.12: Purification of TgPex5c-terminalfollowed by SDS-PAGE . A 100 kDa ladder washed
as a marker on SDS-PAGE gels stained purified HIS-GST-TEV-TgPex5c-terminal gave a single
band of the expected size of 62.5 kDa (A). Fusion protein HIS-GST-TEV-TgPex5c-terminal,
after TEV protease digestion (B) produces TgPex5c-terminalat 35.4 kDa and HIS-GST tag at 29
KDa. Purified TgPex5c-terminal was eluted after passing through a Ni-NTA column (C)
6.6 Pull-Down Assay
Having successfully expressed and purified recombinant TgSCP2 and TgPex5, a
series of experiments were undertaken to investigate the interaction between the
PTS1 end of SCP2 and the C-terminal end of Pex5. A small scale affinity pull
down assay was used to detecti protein-protein interactions. The GST-Trapcolumn
was used to immobilise the fusion tagged TgSCP2PTS1protein which acted as “bait.”
Bound HIS-GST-TEV-TgSCP2PTS1was then used to trap and bind predicted binding
partner, TgPex5c-terminalwhich is untagged. After incubation of this “prey” protein
on the GST-Trapcolumn, and several wash steps, the resulting mixture was analyzed
by SDS-PAGE.
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6.6.1 HIS-GST-TEV-TgSCP2PTS1with purified TgPex5c-terminal
Previous pull-down assays performed by Dr W. A Stanely, (Figure 6.14) showed that
immobilise bait protein HIS-GST-TEV-TgSCP2PTS1bind to purified TgPex5c-terminalon
a GST-Trapcolumn. HIS-GST-TEV-TgSCP2PTS1at 43.4 kDa bound to column and
showed a protein-protein interaction with prey protein TgPex5c-terminal(34.5 kDa)
Figure 6.13: Interaction of TgSCP2PTS1and purified TgPex5c-terminalin vitro. The pull-down
assay was performed using bait HIS-GST-TEV-TgSCP2PTS1. Eluates of the pull-down without
prey protein (Lane 1, negative control) and TgPex5C (Lane 2)
6.6.2 HIS-GST-TEV-TgPex5c-terminal with purified TgSCP2PTS1
Having confirmed a successful interaction between the TgSCP2PTS1 with purified
TgPex5c-terminal, a further pull down assay was carried out to confirm the same in-
teraction using a different bait protein. For this the HIS-GST-TEV-TgPex5c-terminalwas
used with purified TgSCP2PTS1 (Figure 6.14). A fresh GST-Trapcolumn was used to
immobilise the HIS-GST-TEV-TgPex5c-terminal and the column washed to remove
any unbound bait protein (visable in fractions 1-5) (Figure 6.14 A), showing un-
bound HIS-GST-TEV-TgPex5c-terminalat ~62.5 kDa and traces of GST-tag at ~29
kDa. After the application of purified TgSCP2PTS1to the immobilised fusion protein
(Figure 6.14 B) bands at ~29 kDa for the GST-tag and at ~14.6 kDa for unbound
TgSCP2PTS1were detected in fractions 3-8.
Any protein-protein interaction between bait and prey proteins was revealed by
column in fractions 1-3 (*) which shows both HIS-GST-TEV-TgPex5c-terminal(62.5
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kDa) and TgSCP2PTS1(14.6 kDa) coeluting. A protein-protein interaction between
HIS-GST-TEV-TgPex5c-terminaland purified TgSCP2PTS1can be seen in the pull-
down assay (Figure 6.14 C).
Figure 6.14: Interaction of HIS-GST-TEV-TgPEX5c-terminalwith purified TgSCP2PTS1 . in
vitro. Steps 1 and 2 involved loading GST column with fusion protein HIS-GST-TEV-
TgPEX5c-terminaland washing off any unbound bait. Unbound fusion protein is evident on (A)
SDS gel. (B) SDS gel steps 3 and 4 involved loading prey protein TgSCP2PTS1 . and washing away
any unbound purified protein. (C) SDS page shows the GST-tag at 29 KDa and the protein-protein
(*)interaction between HIS-GST-TEV-TgPEX5c-terminaland TgSCP2PTS1 .
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Figure 6.15: Interaction of HIS-GST-TEV-TgSCP2PTS1.with lysate in vitro. Pull down assay
was performed using HIS-GST-TEV-TgSCP2PTS1.bait (*Red). Loading GST column with fusion
protein HIS-GST-TEV-TgSCP2PTS1.followed by lysate addition and several washes. Unbound
fusion protein is evident SDS gel with no trapped prey protein form lysate. SDS also shows the
GST-tag (* Green)
6.6.3 HIS-GST-TEV-TgSCP2PTS1pull down with Toxoplasma
gondii lysate
Having verified a successful interaction with HIS-GST-TEV-TgPex5c-terminaland
purified TgSCP2PTS1 and HIS-GST-TEV-TgSCP2PTS1with purified TgPex5c-terminal.
we decided to use a T. gondii lysate using this pull down method. For bait pro-
tein HIS-GST-TEV-TgSCP2PTS1was immoblised onto a GST-Trap column and freshly
lysed tachyzoite T. gondii, was loaded onto the column. Interestingly, after several
washes, and SDS gel analysis there were no protein-protein interactions with any of
the lysate proteins (Figure 6.15). It is likely that there are insufficient quantities
from the tachyzoites to be detectable in this assay.
In summary, the in vitro analyses of the interaction between TgSCP2PTS1 and
TgPex5c-terminal showed that recombinant proteins expressed in E. coli , can be
successfully isolated. When subjected to pull-down assays, protein-protein inter-
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action were confirmed orientations in both TgPex5 binding to TgSCP2 when the
HIS-GST-TEV-TgPex5c-terminal end was used as the bait and then vice-versa when
HIS-GST-TEV-TgSCP2PTS1was used as bait. These two interchangeable experi-
ments demonstrated that the TgPex5 can bind to the parasite PTS1. However, the
tachyzoite lysate pull-down assay failed to rescue any peroxins when the bait fusion
protein HIS-GST-TEV-TgSCP2PTS1in the tachyzoite form. We therefore explored
this further to examine peroxins produced at the tachyzoite stage using LOPIT
(Localization of organelle proteins by isotope tagging).
6.7 Exploration of Pex proteomics using LOPIT as-
signments
Data provided by Ross Waller University of Cambridge
Proteomic analysis by LOPIT used the method described by [108] to determine
protein distributions. The results (Table 6.1) show un-detectable Pex assignments,
re-affirming that expression of Pex proteins is absent or at least significantly lower in
the tachyzoite stage of the parasite. Pex5, identified by the TDR domain, shows an
ND (non-detectable) level. The proteomic analysis supports the experiments with
the HIS-GST-TEV-TgSCP2PTS1pull down with T. gondii, suggesting that the level
of Pex proteins is too low to be detectable from a the tachyzoite lysate.
6.8 Peroxisomal protein conclusion
TgSCP2PTS1 (-SRL) clearly binds to TgPex5c-terminal parasite binding domain in
vitro as shown by the two binding pull down assays and supports the hypothesis
that the observed co-localisation of ePTS1-tagged GFP is due to direct interaction
within peroxisome-like bodies in Toxoplasma. In addition, expression of heterologous
TgPex5 in a Pex5 knock-out in yeast, highlights the importance of Pex5 within the
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peroxisomal complex by showing that the endogenous fatty acid-degrading enzymes
with or without the PTS1 site involved in the peroxisomal process were activated
and used in the breakdown and utilisation of oleate. In contrast, Toxoplasma Pex5
was unable to direct eGFP-SKL to human fibroblast peroxisomes making it impos-
sible to restore the functionality of their mammalian equivalent Pex5-deficient cells.
Together, the two complementation experiments in yeast and human fibroblasts
showed that TgPex5 is a functional orthologue and that differences in functionality
between the parasite and human Pex5 could be exploited in drug target studies.
Chapter 7
Discussion and conclusions
Despite numerous efforts into the research and development of treatments towards
protozoa, in particular toxoplasmosis and leishmaniasis, there are still many gaps in
the development of new treatment regimes and drug targets. Further information
about the mode of action and exploration of natural products as potential sources of
treatment is essential for treating these debilitating diseases. The work carried out
in this thesis describes the screening of natural compounds against Leishmania and
Toxoplasma, as well as the identification of peroxisomes as a potential drug target
within T. gondii. This chapter summaries and discusses the results outlined in this
study, as well as highlighting the important benefits of using natural products as
potential drugs against Toxoplasma and Leishmania.
7.1 Discussion
7.1.1 Toxoplasma gondii
The T. gondii parasite causes various forms of toxoplasmosis and is treatable in
the acute form of the disease but more difficult to treat in the chronic stages or in
pregnant women [19]. Although there are a range of treatment regimes for T. gondii,
the current front-line drugs are limited due to a rise in drug resistant strains and
120
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also reports of severe side effects [13, 20, 29, 30]. These issues have, created a need
to discover new drug targets and demand for new compounds that are non-toxic
and can be used on the encysted form of the parasite. By exploiting the biology
of T. gondii, we were able to identify peroxisomes as a potential novel drug target
within this obligate parasite. This, alongside the screening of natural compounds
and peroxisome specific inhibitors against T. gondii, may lead to a new repertoire
of compounds.
7.1.1.1 Identifying peroxisomes in Toxoplasma gondii
Chapter 6 of this thesis investigated the existence of peroxisomes in Toxoplasma.
The recent bioinformatic analyses that demonstrated the presence of a family of Pex
proteins in coccidian apicomplexans, but not in other subclasses [109–111], mer-
ited further functional analysis. In previous studies, the existence of Toxoplasma
peroxisomes has proven to be controversial. Toxoplasma catalase (an identifier of
peroxisomes) was localised to peroxisome-like vesicles in one study [52], and in the
same year it was reported that the putative catalase PTS1 failed to direct GFP
to these membrane-bound microbodies [51]. Another PTS1 protein, the sterol car-
rier protein (SCP2), has also been shown to localise to peroxisome-like bodies in
Toxoplasma [50]. To improve the molecular understanding of the putative peroxi-
somal bodies in T. gondii, we conducted a series of cellular and biochemical experi-
ments using the Pex5 orthologue of the parasite. We first established that TgPex5
showed significant similarity with yeast Pex5, especially in the C-terminal domain,
supporting work carried out by others [24, 40, 41, 43, 45]. Furthermore, analyses
of Toxoplasma Pex5 in a  Pex5 yeast strain using a sequence of qualitative and
quantitative methods [42,43,45] confirmed that the Pex5 orthologue was functional
in vitro. Heterologous expression of TgPex5 restored the utilisation of oleate in
Pex5-deficient yeast clearly demonstrating that a complete set of endogenous fatty
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acid-degrading enzymes with, and without, typical PTS1 sequences are recognized
and targeted to peroxisomes by the parasite peroxin. This shared cargo selectivity
of the yeast and Toxoplasma receptor, which included Fox1, was recognized by the
PTS1-independent binding domain and N-terminal of the yeast Pex5 PTS1-binding
region. Importantly, unlike the mammalian orthologue, TgPex5 maintains a Fox1-
binding region (a region involved in peroxisomal b-oxidation). TgPex5 was unable
to direct eGFP-SKL to human fibroblast peroxisomes and thus rescue the import
defect of an equivalent mammalian Pex5-deficient cell line. Taken together, this
data indicates that TgPex5 is a functional orthologue of the yeast protein but not
its human peroxin counterpart. This difference between the Pex proteins of these
two species could be exploited when considering the TgPex5-PTS1 interaction as a
drug target.
In the other, in vitro, studies we investigated protein-protein interactions be-
tween the TgPex5 receptor and its associated protein ligand TgSCP2 in pull down
binding assays. Successful purification of TgPex5C-terminal and TgSCP2PTS1 proteins
allowed us to show protein-protein interaction between Toxoplasma peroxisomal pro-
teins TgPex5C-terminal and TgSCP2PTS1C-terminal and vice versa with TgSCP2PTS1 and
TgPex5C-terminal. The interaction with TgSCP2PTS1, showed that the Toxoplasma
Pex5 can bind to the parasite PTS1. However, a similar pull-down assay designed
to fish for further Pex proteins in tachyzoite lysates was unsuccessful. These findings
were later confirmed by LOPIT data which indicates that the level of Pex proteins
is too low to be detected at this stage of the parasite life cycle.
Localization studies of yeast-derived ePTS1 were sufficient to localise GFP to
peroxisome-like bodies in Toxoplasma and like [50, 52], other PTS1 proteins the
SRL domain clearly binds to the parasite TgPex5 PTS1-binding domain in vitro.
In summary, the investigations carried out here, strongly suggest that this api-
complexan parasite has peroxisomes. The relative lack of structural evidence may be
due to lifecycle-dependent expression, with the peroxins characterised by upregula-
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tion during the extracellular stages of the lifecycle, oocysts and sporozoites. Future
studies should be directed here, rather than at the more tractable, intracellular,
tachyzoite forms [111].
7.1.1.2 Natural products and Pex inhibitor screen
Frontline drugs in the treatment of toxoplasmosis have a higher cure rate in tachy-
zoites, however, current drug therapies are problematic and have extended treat-
ment periods with long lasting toxic side effects when targeting encysted forms of
T. gondii [13,30]. The result is that, available drugs that fail to be effective against
T.gondii tissue cysts, create a challenge when trying to develop compounds with
short treatment courses. Current problems facing toxoplasmosis drug discovery to-
day include finding a novel compound effective against the encysted parasite [8,30].
Previous research has shown that the repurposing of medicines for protozoa is one
way of tackling treatment [1,7]. Pex5-Pex14 inhibitors (Chapter 5) have previously
been identified as disrupting glycosomal protein import and killing trypanosomes by
affecting the Pex5-interaction in T. brucei and have been shown to be active against
Pex14 in other related protozoa, such as T. cruzi and Leishmania [102]. Here we de-
cided to screen these inhibitors against T. gondii intracellular tachyzoites, and were
able to identify 11 Pex5-Pex14 inhibitors that gave an EC50 < 10 mM. However,
despite the significant inhibition rate the majority of the compounds demonstrated
high mammalian toxicity. Optimization of these compounds to make them non-
toxic to mammalian cells could be pursued and lead to the development of a new
class of specific Pex protein inhibitor for T.gondii. In addition to the repurpos-
ing of the Pex5-Pex14 inhibitors we also tested a natural compound Aureobasidin
A (AbA) and several derivatives against Toxoplasma. For this an existing brady-
zoite in vitro drug assay [78,92] was optimized to test AbA and derivatives against
encysted forms of T.gondii. AbA, Compound 3, and Compound 20 demonstrated
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good efficacy against these forms, suggesting that the cyclic depsipeptides represent
promising candidates for therapies to treat both acute and chronic toxoplasmosis.
7.1.2 Leishmania mexicana
Cutaneous Leishmaniasis is caused by New World species L. mexicana, and with
recent publications showing the rise in the cases of leishmaniasis at a global level,
investigations into the use of natural compounds for the treatment of various forms
of leishmaniasis has become crucial [15, 28, 56]. As for toxoplasmosis, the current
treatments are both toxic, and have increasing reports of resistance. To improve and
increase the number potential antileishmanials, researchers have screened naturally-
derived compounds in in vitro assays [60,62,66,69].
7.1.2.1 Natural product screen
In Chapter 3 using an iterative screening and fractionation approach we ’mined’ the
HDLSX Hypha compound library of 313 fungal extracts which contain a large num-
ber of small molecule secondary metabolites. Using well established Leishmania in
vitro assays [54, 87] we were able to identify four compounds with anti-leishmanial
properties (EC50 of less than 10 mM) in the axenic assay and L. mexicana intra-
macrophage and two compounds showing low mammalian cytotoxicity. HD871-2
and the pure secondary fractionation component, HD871-1 with a molecular weight
of 262, were identified as potent antileishmanials. HD871-1 was characterised as a
novel bisabolane sesquiterpene with a high degree of oxygenation and unsaturation
and structural similarities to cheimonophyllons A-E. These bisabolane sesquiter-
penes isolated from fermentations of the basidiomycete Cheimonophyllum candidis-
simum, are known to possess nematicidal properties [112]. The similarity of HD871-
1 to cheimonophyllons puts this molecule in the same class of compounds, which
7.1. Discussion 125
potentially representent a new class of broad-spectrum anti-parasitics. In order to
moveforward and develop antileishmanials, the identification of the mode of action
was key, and here we carried out a metabolomic study on both HD871-1 and HD871-
2.
7.1.2.2 Metabolomic analyses of HD871-1 and HD871-2
To begin deconvolution of the target of HD871-1 and HD871-2, in Chapter 4,
metabolomics was used to identify changes to the metabolic network of L. mexicana
amastigotes exposed to these compounds. Using a 36 hour time point and a com-
pound dose 2-fold higher than the EC50, a number of clear changes to metabolism
occurred. These included changes in the deoxynucleotide pool and therefore repre-
sent possible effects on nucleotide metabolism, although whether this was the cause
of cell death, or a secondary effect due to other changes, is not clear. A reduction
in the levels of the chief redox reactive thiol trypanothione and accumulation of
cystine pointed to oxidative stress being induced by HD871-1 and HD871-2. Since
both reduced and oxidised trypanothione was diminished, as was glutathione, a pos-
sible role is drug binding prior to efflux from the cell, as apparent with the parasite
response to antimony [113]. Trypanothione enzymes potentially targeted by these
compounds would be worthy of future investigation as has been shown when eflor-
nithine is used against T. brucei [4]. In Leishmania donovani for example, Sb(III)
interferes with thiol metabolism, leading to decreased thiol-buffering capacity, but
is also involved in the inhibition of trypanothione reductase which results in a lethal
imbalance in thiol homeostasis [114]. This similarity of HD871-1 and HD871-2 to
Sb(III) is of particular interest as the effects of the biological activity of our tested
compounds seem to show similar the mode of action of Sb(III), which is related to
clinically prescribed Sb(V) [114].
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7.2 Conclusions
The results described in this thesis illustrate the discovery of two novel natural com-
pounds that are active against L. mexicana, are non-toxic to mammalian cells, and
have a low EC50, with a suggested mode of action. This new knowledge allowed the
identification of a novel class of compounds which could be used in the future treat-
ment of leishmaniasis. The other breakthrough investigation was the confirmation
of peroxisomes in Toxoplasma and we were able to identify these as organelles for
further drug target studies.
7.3 Proposed Future work
From the work carried out in this thesis, the following key areas are identified as
potential avenues for future work:
Further confirmation on the mode of action of compounds HD871-1 and HD871-
2; they could both be screened in trypanothione reductase and synthase assays to
revel the mode of action, similar to the kinetic analysis experiments of these enzymes
carried out in Trypansoma brucei [5]
Breakthrough knowledge of peroxisomes in Toxoplasma could be exploited by con-
sidering the TgPex5-PTS1 interaction as a potential drug target, as there is a clear
difference between the Pex proteins from humans and this apicomplexan parasite.
The Pex5-PTS1 complex has been examined in Trypansoma brucei as a potential
drug target [115].
Exploration into peroxisomes in the extracellular stages of T. gondii is essential
to fully understand the role of peroxisomes in Toxoplasma oocysts. In addition,
further investigation into other Pex proteins such as TgPex7 and TgPex14 and
functional analyses using technologies such as CRISPR-Cas9 are essential for fuller
understanding [116].
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Appendix A
Basic and Auxiliary Results
A.0.1 Restriction site mapping of TgSCP2TUB8mycGFPmyoATy-
HX colon
Insertion of TgSCP2 were confirmed by two methods; restriction site mapping using
BamHI for TgSCP2TUB8mycGFPmyoATy-HX as shown in Figure A.1 Lane 1 =
10 000 bp ladder, Lane 2 = as expected band (A) cut by EcoRI gave a band at 8494
bp, Lane 3 = As expected band (B) and (C) cut by BamHI gave bands at 7761 bp
and 733 bp respectively. This confirmed successful cloning of TgSCP2 into plasmid
(TUB8mycGFPmyoATy-HX)
A.1 Restriction site mapping of TgPex5-pIRES2-
EGFP-SKL andTgPex7-pIRES2-EGFP-SKL colons
Insertion of TgPex5 and TgPex7 were confirmed by two methods; restriction site
mapping using BamHI for TgPex5-pIRES2-EGFP-SKL and BstBI TgPex7-pIRES2-
EGFP-SKL shown in Figure A.2 . In gel image (A) Lane 1 = 10 000 bp ladder.
Lane 2 is TgPex5-pIRES2-EGFP-SKL digestion with BamHI gave as expected 2
bands one at 5431 bp and the other at 2568 bp. In gel image (B) Lane 1 = 10
000 bp ladder. Lane 2 is TgPex7-pIRES2-EGFP-SKL digestion with BstBI gave 3
expected bands at 4378 bp, 1921 bp and 362 bp. This mapping confirmed successful
cloning of TgPex5 and TgPex7 into plasmid (pIRES2-EGFP-SKL)
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Figure A.1: Restriction Site Mapping TgSCP2 in Plasmid; Lane 1 = 10 000 bp ladder, Lane 2
= (A) cut by EcoRI gave a band at 8494 bp, Lane 3 = band (B) and (C) cut by BamHI gave
bands at 7761 bp and 733 bp respectively.
Figure A.2: Restriction Site Mapping TgPex5 and TgPex7 in Yeast Plasmid; (A) Lane 1 = 10
000 bp ladder. Lane 2 is TgPex5-pIRES2-EGFP-SKL digestion with BamHI gave 2 bands at 5431
bp and 2568 bp. (B) Lane 1 = 10 000 bp ladder. Lane 2 is TgPex7-pIRES2-EGFP-SKL BstBI
digestion gave bands at 4378 bp, 1921 bp and 362 bp.
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Figure A.3: Restriction Site Mapping TgPex5 and TgPex7 in Human Plasmid; (A) Lane 1 = 10
000 bp ladder. Lane 2 is TgPex5-pIRES2-EGFP-SKL digestion with BamHI gave 2 bands at 5431
bp and 2568 bp. (B) Lane 1 = 10 000 bp ladder. Lane 2 is TgPex7-pIRES2-EGFP-SKL BstBI
digestion gave bands at 4378 bp, 1921 bp and 362 bp.
A.1.1 Restriction site mapping of TgPex5-pRS416-WT and TgPex7-
pRS416-WT colons
Insertion of amplicons TgPex5 and TgPex7 were confirmed by two methods; restric-
tion site mapping using BamHI for TgPex5-pRS416-WT and SacII for TgPex7-
pRS416-WT as shown in Figure A.3. In gel(A) Lane 1 = 10 000 bp ladder. Lane
2 with TgPex5-pRS416-WT plasmid after digestion with BamHI gave 2 expected
bands one at 5200 bp and the other at 3100 bp. In gel (B) Lane 1 = 10 000 bp
ladder. Lane 2 is TgPex7-pRS416-WT digestion with SacII gave 3 expected bands
at 5589 bp, 874 bp and 499 bp. This confirmed successful cloning into the human
pRS416-WT plasmid vector.
A.2 Macro data sheet
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